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MANNHEIM/A HAEMOLYTICA CHIMERIC 
OUTER MEMBRANE PROTEIN PLPE AND 
LEUKOTOXIN EPITOPES AS A VACCINE OR 
VACCINE COMPONENT AGAINST SHIPPING 
FEVER 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
U.S. Pat. No. 5,055,400 to Lo et al., (Oct. 8, 1991) discloses 
the Pasteurella haemolytica leukotoxin gene and protein. 
U.S. Pat. No. 5,476,657 (Potter, Dec. 19, 1995) and U.S. Pat. 
No. 5,871,750 (Potter, Feb. 16, 1991) disclose vaccines 
comprising Pasteurella haemolytica leukotoxin or trun-
cated forms of the leukotoxin. 
U.S. Pat. No. 5,708,155 (Potter et al., Jan. 13, 1998) and U.S. 
This application claims benefit of U.S. provisional patent 10 
application 60/757,342, filed Jan. 9, 2006, and is a continua-
tion-in-part of U.S. patent application Ser. No. 11/235,982, 
filed Sep. 27, 2005, now issued U.S. Pat. No. 7,144,580, 
which is a divisional of U.S. patent application Ser. No. 
10/695,544, filed Oct 29, 2003, now abandoned, which 15 
claimed benefit ofU.S. provisional patent application 60/422, 
305, filed Oct 30, 2002, the complete contents of each of 
which are hereby incorporated by reference. 
Pat. No. 6,797,272 (Potter et al., Sep. 28, 2004) disclose 
vaccines comprised of chimeras of Pasteurella 
haemolytica leukotoxin and an antigen such as somatosta-
tin (SRIF), gonadotropin releasing hormone (GnRH), or 
rotavirus viral protein 4 (VP4). 
U.S. Pat. No. 5,238,823 (Potter et al., Aug. 24, 1993), U.S. 
Pat. No. 5,273,889 (Potter et al., Dec. 28, 1993), U.S. Pat. 
No. 5,594,107 (Potter et al., Jan. 14, 1997) and U.S. Pat. 
No. 6,096,320 (Potter et al., 5 Aug. 1, 2000), disclose 
vaccines of chimeric proteins comprising Pasteurella 
haemolytica leukotoxin or an antigenic fragment thereof, 
and a cytokine such as gamma-interferon or interleukin-2. This invention was made using funds from grants from the 
United States Department of Agriculture having grant num-
ber USDA-NRI 2002-35204-12250. The United States gov-
ermnent may have certain rights in this invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
20 U.S. Pat. No. 5,871,750 (Potter, Feb. 16, 1999) discloses 
vaccine compositions comprising a truncated Pasteurella 
haemolytica leukotoxin. Other Pasteurella haemolytica 
cell surface antigenic proteins are also disclosed (fimbrial 
25 
protein, plasmin receptor protein, and 50K outer mem-
brane protein. 
U.S. Pat. No. 5,723,129 (Potter eta!., Mar. 3, 1998), U.S. Pat. 
The present invention relates generally to the prevention of 
bovine respiratory disease (BRD) and, in particular, its most 
severe form, termed "shipping fever". More specifically, the 
present invention relates to the use of chimeric proteins com- 30 
prising immunodominant epitopes of recombinant Mannhe-
imia haemolytica outer membrane protein PlpE, and immu-
nodominant epitopes of recombinant M. haemolytica 
leukotoxin as a vaccine or vaccine component against ship-
ping fever. 35 
No. 5,837,268 (Potter et al., Nov. 17, 1998), U.S. Pat. No. 
6,022,960 (Potter et al., Feb. 8, 2000) and U.S. Pat. No. 
6,521,746 (Potter et al., Feb. 18, 2003) disclose vaccines 
comprised of chimeras of leukotoxin and gonadotropin 
releasing hormone (GnRH) multimers. 
U.S. Pat. No. 6,475,754 (Bemis et al., Nov. 5, 2002) discloses 
an antigenic chimeric protein comprising fimbrial protein 
of Bordetella bronchiseptica and leukotoxin of M. 
haemolytica. 
2. Background 
BRD is the major cause of beef cattle morbidity and mor-
tality and of economic losses to the beef cattle industry. The 
cost of BRD to beef cattle producers approaches $1 billion 
annually. BRD arises from the interaction of numerous con-
tributing factors including physical stresses associated with 
weaning, shipment, inclement weather, and overcrowding 
coupled with viral and bacterial infections. The end result in 
severe cases is colonization of the lungs with pathogenic 
bacteria resulting in severe pneumonia. Pasteurella multo-
cida, Haemophilus somnus and Mannheimia (formerly Pas-
teurella) haemolytica are associated with bovine pneumonia. 
However, Mannheimia haemolytica serotype l(Sl) is by 
far the most important and commonly isolated bacterial 
pathogen in development of the often-fatal fibrinous pleurop-
neumonia in beef cattle known as pneumonic pasteurellosis 
or "shipping fever". 
Prevention and control of shipping fever in feedlots is 
currently partially addressed by three different mechanisms: 
antibiotic treatment upon arrival of cattle at the feedlot, anti-
biotic therapy for sick cattle, and vaccination against BRD 
viruses and M. haemolytica. The extensive use of antibiotics 
to control shipping fever increases the possibility of antibiotic 
residues in meat and the development of drug-resistant bac-
teria in cattle, including those bacteria with potential impact 
on human health such as Salmonella and Escherichia coli 
0157:H7. 
Viral and bacterial vaccines for the control of shipping 
fever have been used for many years. Despite their availabil-
ity, the disease continues to be a major bovine health problem. 
Attempts to develop a vaccine include the following: 
Immunity against M. haemolytica is thought to be prima-
rily through production of serum antibodies that neutralize 
the secreted leukotoxin (LKT) and antibodies against surface 
antigens. The specific surface antigens that are important in 
40 stimulating host immunity to M. haemolytica are not known; 
however, several studies point towards the importance of 
outer membrane proteins (OMPs). Pandher et al. demon-
strated 21 surface-exposed immunogenic outer membrane 
proteins in M. haemolytica Sl using protease treatment and 
45 Western blotting. (Pandher K, Murphy G L, Confer A W. 
Identification of immunogenic, surface-exposed outer mem-
brane proteins of Pasteurella haemolytica serotype 1. Vet 
Microbial 1999; 65: 215-26) High antibody responses to 
outer membranes, as measured by ELISA, and to several 
50 specific OMPs, as measured by quantitative Western Blot-
ting, consistently correlated with resistance to challenge with 
virulent M. haemolytica Sl (Confer A W, McCraw R D, 
Durham J A, Morton R J, Panciera R J. Serum antibody 
responses of cattle to iron-regulated outer membrane proteins 
55 of Pasteurella haemolytica Al. Vet Immuno!Immunopathol 
1995; 47: 101-10 and Mosier DA, Simons KR, Confer AW, 
Panciera R J, Clinkenbeard K D. Pasteurella haemolytica 
antigens associated with resistance to pneumonic pasteurel-
losis. Infect Immun 1989; 57: 711-6). Vaccination of cattle 
60 with OMP-enriched cellular fractions, from M. haemolytica 
S 1 significantly enhanced resistance of cattle against experi-
mental challenge in the absence of antibodies to LKT. (Mor-
ton R J, Panciera R J, Fulton R W, Frank G H, Ewing SA, 
Homer J T, Confer A W. Vaccination of cattle with outer 
65 membrane protein-enriched fractions of Pasteurella 
haemolytica and resistance against experimental challenge 
exposure. Am J Vet Res 1995; 56: 875-879) However, the 
US 7,794,734 B2 
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extraction procedure for bacterial outer membranes is time 
consuming and expensive, making use of purified OMPs as a 
component of a M. haemolytica vaccine impractical due to 
cost. Thus, it can be appreciated that the identification of 
specific, surface exposed immunogenic M. haemolytica 
OMPs that would stimulate strong antibody responses is 
highly desirable. Cloning and expression of the appropriate 
gene(s) and production ofrecombinant OMP could then be 
achieved inexpensively. 
One of the M. haemolytica OMPs to which high antibody 
responses correlated with resistance against experimental 
challenge is a major 45 kDa OMP. Prior studies were under-
taken to clone and characterize that protein. In 1998, Pandher 
et al. reported the cloning, sequencing and characterization of 
the gene forthemajor45-kDaM. haemolytica Sl outer mem-
brane lipoprotein, designated PlpE. (Pandher K, Confer AW, 
Murphy G L. Genetic and immunologic analyses of PlpE, a 
lipoprotein important in complement-mediated killing of 
Pasteurella haemolytica serotype 1. Infect Immun 1998; 66: 
5613-9, which publication is incorporated herein by refer-
ence) PlpE was found genetically to have 32-35% similarity 
to an immunogenic lipoprotein, OmIA, demonstrated inActi-
nobacillus pleuropneumoniae serotypes 1 and 5. Affinity-
purified, anti-PlpE antibodies recognized an OMP in all sero-
types of M. haemolytica except in serotype 11. In addition, 
PlpE was determined to be surface-exposed, and in comple-
ment-mediated killing assays, a significant reduction was 
observed in killing of M. haemolytica when bovine immune 
serum that was depleted of anti-PlpE antibodies was used as 
the source of antibody, suggesting that antibodies against 
PlpE may contribute to host defense against the bacterium. 
4 
composition further comprises a pharmaceutically accept-
able carrier or diluent and adjuvant. 
In another aspect of the invention there are provided meth-
ods for inducing an immune response in cattle to provide 
5 immune protection against BRD and/or shipping fever, the 
method comprising administering to an at-risk animal an 
effective amount of a vaccine composition comprising rPlpE 
or conservatively modified variants thereof alone or in com-
bination with an adjuvant and/or other immunogens to pro-
10 vide a means to reduce the risk ofBRD, wherein the vaccine 
composition further comprises a pharmaceutically accept-
able carrier or diluent. 
Most of the structure of an OMP molecule would play no 
significant role in inducing protective immune responses, 
15 because extended portions of the molecule are buried, unex-
posed, in the outer membrane. Instead, immunity can be 
attributed to only short, surface-exposed epitopes of these 
proteins. Identification of such surface-exposed epitopes as 
protective antigens in animal models has been the target of 
20 peptide vaccine design strategies for various pathogenic bac-
teria. Because of M. haemolytica PlpE's potential as an 
important immunogen, studies were undertaken to character-
ize surface-exposed and immunologically important epitopes 
of PlpE and to produce and test recombinant epitopes corre-
25 sponding thereto. Thus, in another aspect of the invention 
there are provided immunologically important epitopes of 
rPlpE for use in vaccines and related methodologies. 
In another aspect of the invention, chimeric proteins are 
provided which contain one or more copies of an immun-
30 odominant epitope of M. haemolytica rPlpE in combination 
with an immunodominant epitope of M. haemolytica leuko-
Because of the economic constraints of the cattle industry, 
bovine vaccines must be low in cost. Therefore, current M. 
haemolytica vaccines are crude, usually consisting of a cul-
ture supernatant, which contains M. haemolytica leukotoxin 35 
and sloughed surface proteins, and/or the killed bacterium. 
Perino and Hunsaker reviewed published field studies on 
commercial M. haemolytica vaccines and found that efficacy 
could be established in only 50% of the trials. (Bov Practitio-
ner 1997; 31: 59-66). There is thus an ongoing need for 40 
improvement in M. haemolytica vaccines, and for the devel-
opment of improved methods and compositions for protect-
ing cattle against shipping fever. 
toxin. 
The present invention provides an immunogenic composi-
tion which includes at least one chimeric protein comprising: 
one or more copies of an immunodominant epitope of recom-
binant Mannheimia haemolytica PlpE, and one or more cop-
ies of an immunodominant epitope of recombinant Mannhe-
imia haemolytica leukotoxin (LKT); and a physiologically 
compatible carrier. In one embodiment, the immunodomi-
nant epitope of recombinant Mannheimia haemolytica PlpE 
is R2 and is represented by SEQ ID NO: 19. In one embodi-
ment, the immunodominant epitope of recombinant Mannhe-
imia haemolytica LKT is mLKT A and is represented by SEQ 
ID NO: 21. In one embodiment, the at least one chimeric 
SUMMARY OF THE INVENTION 
In connection with the present invention, the gene for M. 
haemolytica outer membrane protein PlpE was cloned and 
the recombinant PlpE (rPlpE) was purified and used in immu-
nological and vaccination studies. It was discovered that adju-
vanted rPlpE was highly immunogenic in cattle, and vacci-
nation of cattle with 100 µg of rPlpE markedly enhanced 
resistance against experimental challenge with virulent M. 
haemolytica. It was also discovered that the addition of rPlpE 
to a commercial M. haemolytica vaccine significantly 
enhanced (p<0.05) protection afforded by the vaccine against 
experimental challenge. 
Thus, in one aspect of the present invention there are pro-
vided vaccine compositions comprising rPlpE or conserva-
tively modified variants thereof separately or which may 
optionally be combined with adjuvant to enhance the protec-
tion efficacy of vaccine preparations against BRD and/or 
shipping fever, wherein the vaccine composition further com-
prises a pharmaceutically acceptable carrier or diluent. The 
rPlpE also may optionally be combined with other immuno-
gens and/or existing commercially available vaccines to form 
an augmented vaccine composition, wherein the vaccine 
45 protein further comprises a leader sequence, for example, the 
glutathione-S-transferase leader sequence. The at least one 
chimeric protein may further comprises one or more spacer 
peptides. In one embodiment of the invention, the at least one 
chimeric protein comprises two copies of the immunodomi-
50 nant epitope of recombinant Mannheimia haemolytica PlpE 
and two copies of the immunodominant epitope ofrecombi-
nant Mannheimia haemolytica LKT. 
The invention further provides a chimeric protein which 
comprises: one or more copies of an immunodominant 
55 epitope of recombinant Mannheimia haemolytica PlpE, and 
one or more copies of an immunodominant epitope of recom-
binant Mannheimia haemolytica leukotoxin (LKT). In one 
embodiment, the immunodominant epitope of recombinant 
Mannheimia haemolytica PlpE is R2 as represented by SEQ 
60 ID NO: 19. In one embodiment, the immunodominant 
epitope of recombinant Mannheimia haemolytica LKT is 
mLKT A as represented by SEQ ID NO:21. In another 
embodiment, the chimeric protein further comprises a leader 
sequence, which may be, for example, the glutathione-S-
65 transferase leader sequence. In another embodiment, the chi-
meric protein comprises one or more spacer peptides. In one 
embodiment of the invention, the chimeric protein comprises 
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two copies of the immunodominant epitope of recombinant 
Mannheimia haemolytica PlpE and two copies of the immu-
nodominant epitope of recombinant Mannheimia 
haemolytica LKT. 
The invention also provides a vaccine preparation which 5 
comprises at least one chimeric protein comprising: one or 
more copies of an immunodominant epitope of recombinant 
Mannheimia haemolytica PlpE, and one or more copies of an 
immunodominant epitope of recombinant Mannheimia 
haemolytica leukotoxin (LKT); and a physiologically com- 10 
patible carrier. In one embodiment, the immunodominant 
epitope of recombinant Mannheimia haemolytica PlpE is R2 
6 
embodiment, the at least one chimeric protein further com-
prises a leader sequence, one example of which is the glu-
tathione-S-transferase leader sequence. In another embodi-
ment, the at least one chimeric protein further comprises one 
or more spacer peptides In addition, in one embodiment, the 
at least one chimeric protein comprises two copies of the 
immunodominant epitope of recombinant Mannheimia 
haemolytica PlpE and two copies of the immunodominant 
epitope of recombinant Mannheimia haemolytica LKT. 
A better understanding of the present invention, its several 
aspects, and its advantages will become apparent to those 
skilled in the art from the following detailed description, 
taken in conjunction with the attached figures, wherein there 
is described the preferred embodiment of the invention, sim-
ply by way of illustration of the best mode contemplated for 
carrying out the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph depicting anti-PlpE antibody response of 
6 cattle vaccinated with 100 µg ofrPlpE on day 0. 
as represented by SEQ ID NO: 19. In one embodiment of the 
invention, the immunodominant epitope of recombinant 
Mannheimia haemolytica LKT is mLKT A as represented by 15 
SEQ ID NO: 21. In another embodiment, the at least one 
chimeric protein further comprises a leader sequence, one 
example of which is the glutathione-S-transferase leader 
sequence. In another embodiment, the at least one chimeric 
protein further comprises one or more spacer peptides. In 20 
other embodiments, the at least one chimeric protein com-
prises two copies of the immunodominant epitope ofrecom-
binant Mannheimia haemolytica PlpE and two copies of the 
immunodominant epitope of recombinant Mannheimia 
haemolytica LKT. 
FIG. 2 is a bar graph depicting anti-PlpE antibody 
responses of cattle that spontaneously seroconverted to M. 
haemolytica (Natural Infection), vaccinated with commercial 
25 vaccines, M. haemolytica outer membranes (OMP), or liveM. 
haemolytica. In yet other embodiments, the vaccine preparation of also 
includes an adjuvant. 
The present invention also provides a method of eliciting 
an immune response to Mannheimia haemolytica in a mam-
mal. The method comprises the step of administering to the 30 
mammal at least one chimeric protein comprising: one or 
more copies of an immunodominant epitope of recombinant 
Mannheimia. haemolytica PlpE, and one or more copies of an 
immunodominant epitope of recombinant Mannheimia 
haemolytica leukotoxin (LKT). In one embodiment, the 35 
immunodominant epitope of recombinant Mannheimia 
haemolytica PlpE is R2 as represented by SEQ ID NO: 19. In 
one embodiment of the invention, the immunodominant 
epitope of recombinant Mannheimia haemolytica LKT is 
mLKT A as represented by SEQ ID NO: 21. In another 40 
embodiment, the at least one chimeric protein further com-
prises a leader sequence, one example of which is the glu-
tathione-S-transferase leader sequence. In another embodi-
ment, the at least one chimeric protein further comprises one 
or more spacer peptides. 
In another embodiment, the at least one chimeric protein 
comprises two copies of the immunodominant epitope of 
recombinant Mannheimia haemolytica PlpE and two copies 
45 
of the immunodominant epitope of recombinant Mannheimia 
haemolytica LKT. In one embodiment of the invention, the 50 
mammal is bovine. 
The invention also provides a method of vaccinating cattle 
to prevent or attenuate disease symptoms caused by Mannhe-
imia haemolytica. The method comprises the step of admin-
istering to the cattle at least one chimeric protein comprising: 55 
one or more copies of an immunodominant epitope of recom-
binant Mannheimia haemolytica PlpE, and one or more cop-
ies of an immunodominant epitope of recombinant Mannhe-
imia haemolytica leukotoxin (LKT). According to the 
method, the at least one chimeric protein is administered in an 60 
amount sufficient to prevent or attenuate disease symptoms 
caused by Mannheimia haemolytica. In one embodiment, the 
immunodominant epitope of recombinant Mannheimia 
haemolytica PlpE is R2 as represented by SEQ ID NO: 19. In 
one embodiment of the invention, the immunodominant 65 
epitope of recombinant Mannheimia haemolytica LKT is 
mLKT A as represented by SEQ ID NO: 21. In another 
FIG. 3 is a bar graph depicting anti-PlpE antibodies for 
cattle vaccinated with commercial M. haemolytica vaccines 
or 100 µg ofrPlpE. 
FIG. 4 A-C is a series of graphs depicting anti-PlpE (A), 
anti-M. haemolytica leukotoxin (B), and anti-M. haemolytica 
whole cells (C) in cattle vaccinated with PRESPONSE, PRE-
SPONSE plus 1 00µg of rPlpE, or nonvaccinated. 
FIG. 5 is a graph depicting rectal temperatures of calves 
after challenge. 
FIG. 6 is a graphical depiction of bovine antibody against 
surface exposed components of PlpE that was affinity purified 
with intact M. haemolytica cells and used to probe a peptide 
array. Densitometric analysis demonstrated a total of 8 dis-
tinct antigenic regions (El-8) in PlpE with E2 being the 
largest and E4 having the highest densitometric signal. 
FIG. 7 A-B. A, amino acid sequence ofR2 immunodomi-
nant region (epitope) of rPlpE (SEQ ID NO: 19); B, DNA 
sequence encoding R2 (SEQ ID NO: 20). 
FIG. 8 A-B. A, amino acid sequence ofmLKTA (SEQ ID 
NO: 21 ); B, DNA sequence encoding mLKTA (SEQ ID NO: 
22). 
FIG. 9 A-F. Schematic representations of plasmids encod-
ing the chimeric proteins of the invention. A, plasmid encod-
ing SAC86; B, plasmid encoding SAC 87; C, plasmid encod-
ing SAC88; D, plasmid encoding SAC89; E, plasmid 
encoding SAC91; F, linearized versions of the plasmids. 
FIG. 10 A-B. A, amino acid sequence of SAC86 chimera 
(SEQ ID NO: 23 ). Sequences of spacer peptides are shown in 
italics; sequences from PlpE are shown in bold with a solid 
underline; and sequences from LKT are shown in bold with a 
dotted underline; B, nucleic acid sequence encoding SAC86 
chimera (SEQ ID NO: 24). 
FIG. 11 A-B. A, amino acid sequence of SAC87 chimera 
(SEQ ID NO: 25). Sequences of spacer peptides are shown in 
italics; sequences from PlpE are shown in bold with a solid 
underline; and sequences from LKT are shown in bold with a 
dotted underline; B, nucleic acid sequence encoding SAC87 
chimera.(SEQ ID NO: 26). 
FIG. 12 A-B. A, amino acid sequence of SAC88 chimera 
(SEQ ID NO: 27). Sequences of spacer peptides are shown in 
italics; sequences from PlpE are shown in bold with a solid 
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underline; and sequences from LKT are shown in bold with a 
dotted underline; B, nucleic acid sequence encoding SAC88 
chimera (SEQ ID NO: 28). 
8 
FIG. 13 A-B. A, amino acid sequence of SAC89 chimera 
(SEQ ID NO: 29); B, nucleic acid sequence encoding SAC89 5 
chimera (SEQ ID NO: 30). For both A and B, sequences of 
spacer peptides are shown in italics; sequences from PlpE are 
shown in bold with a solid underline; and sequences from 
LKT are shown in bold with a dotted underline. 
FIA=Freund's IncompleteAdjuvant; TM=TiterMax®. 10 
The experiments described and non-limiting examples 
provided hereinafter demonstrate that cattle immunized with 
rPlpE and/or epitopes thereof, or with chimeric proteins that 
include the immunodominant PlpE regions and mLKTA 
epitopes (particularly in multiple copies) are unexpectedly 
better protected against infection following challenge with M. 
haemolytica than cattle immunized with existing commer-
cially available vaccines. 
EXAMPLE 1 
FIG. 14 A-B. A, amino acid sequence of SAC91 chimera 
(SEQ ID NO: 31 ). Sequences of spacer peptides are shown in 
italics; sequences from PlpE are shown in bold with a solid 
underline; and sequences from LKT are shown in bold with a 
dotted underline; B, nucleic acid sequence encoding SAC91 15 
chimera (SEQ ID NO: 32). 
Immunogenicity of rPlpE and Vaccine Preparation 
Studies were undertaken to determine the immunogenicity 
ofouter membrane lipoprotein PlpE fromM. haemolytica S 1, 
to determine if commercial vaccines stimulate antibodies to 
it, and examine if addition of recombinant PlpE to a commer-
cial M. haemolytica vaccine would augment vaccine-induced 
immunity. 
FIG. 15 A-F. Data from endpoint titrations of mouse anti-
bodies against rPlpE and LKTA. A, using 25, 50 or 75 µg of 
SAC86 and SAC87 proteins; B, using 25, 50 or 75 µg of 
SAC88 and SAC89 proteins. 
FIG. 16. S=ary ofantibody responses to PlpE and LKT 
via single dilution ELISA. 
FIG. 17 A-B. Quantification of Western blot data using 
densitometric analysis. A, blots against LKT; B, blots against 
PlpE. 
FIG. 18. LKT neutralization activity of murine anti-chi-
menc immune sera. 
FIG. 19. Bactericidal activity of murine anti-SAC89 hyper-
immune sera compared to anti-PlpE hyper-immune calf 
serunJ. 
FIG. 20 A-D. Antibody responses of cattle vaccinated with 
PBS plus adjuvant or 100 µg of SAC89 plus adjuvant. Data 
are expressed as nanograms of immunoglobulin binding to 
the antigen in ELISAs. A, antibodies to whole cells; B, anti-
bodies to Leukotoxin; C, antibodies to PlpE; D, antibodies to 
SAC89. 
DETAILED DESCRIPTION OF THE INVENTION 
The invention is not limited in its application to the details 
of the embodiments and steps described herein. The invention 
is capable of other embodiments and of being practiced or 
carried out in a variety of ways. It is to be understood that the 
phraseology and terminology employed herein is for the pur-
pose of description and not of limitation. 
In accordance with the present invention there are provided 
new vaccine preparations against BRD and shipping fever 
through the use of discrete recombinant PlpE and subunits of 
rPlpE containing immunoprotective regions. In one aspect, 
only rPlpE or immunoprotective and functional regions 
thereof are utilized as the antigenic component of the vaccine. 
In another aspect, rPlpE or subunits thereof are utilized in 
combination with other antigen components, such as leuko-
toxin (LKT). 
20 
1. Materials and Methods 
1.1. Bacterial Culture. 
M. haemolytica S 1 Oklahoma Strain was used for serology 
antigen preparation and for challenge of animals. Frozen 
25 stock cultures were plated onto brain-heart infusion (BHI) 
and grown at 37° C. in a 5% CO2 environment for 18 hours. 
An isolated colony from each was propagated in 10 ml BHI 
broth with rotatory shaking at 120 oscillations/min. for 18 
hours at 3 7° C. 100 µl of suspension was added to 1 L of BHI 
30 broth and grown overnight. The bacteria were sedimented by 
centrifugation at 6000 xg for 15 minutes, washed in 125 ml 
sterile phosphate buffered saline (PBS) and re-centrifuged as 
above 6000 xg for 15 minutes. The bacteria were re-sus-
pended in PBS and adjusted spectrophotometrically to a final 
35 concentration of approximately 1.0xl09 CFU/ml (optical 
density of A600=0.65). 
1.2. Cloning and Purification of PlpE 
The truncated form of plpE lacking the sequence encoding 
40 the putative signal peptide was amplified from pB4522 (Pan-
dher et. al., 1998, supra) with the help of a forward primer 
starting 58 nucleotides into the 5'-end and priming into the 
open reading frame of plpE and a reverse primer which is 
complementary to the 3'-end of the gene. The amplimer was 
45 cut with BamHI and HindIII and ligated into an expression 
vector, pRSETA, cut with the same restriction enzymes. 
Competent E. coli DH5a were transformed with the ligation 
mixture and transformants were plated on Luria-Bertani (LB) 
agar plates with 50 µg/ml of ampicillin. Transformants were 
50 screened and appropriate subclones were identified. Plasmid 
DNA isolated from such subclones was submitted to the 
Oklahoma State University Core Facility where the nucle-
otide sequence was determined by theABI Model 3700 (Bio-
Sciences) automated DNA sequencing system (SEQ ID NO: 
55 1 ). Once the nucleotide sequence of a representative subclone 
was compared to that deposited in the GenBauk (AF059036), 
the recombinant plasmid was introduced into BL21 (DE3) 
pLysS by transformation to express and purify rPlpE (SEQ ID 
In yet another aspect, the invention provides chimeras 
(both proteins and the nucleic acids that encode them) of the 
major surface-exposed epitope of PlpE ( designated herein as 
either "E2" or "R2") and a minimal leukotoxin A fragment 
("mLKTA"). In some embodiments, the chimeras include a 
leader sequence such as the GST leader sequence. In some 60 
embodiments, the antigenic regions (R2 and MLKTA) are 
present in multiple copies in the chimera., the multiple copies 
being separated by spacer peptides. 
NO: 2). 
The expression of rPlpE was done according to the proto-
col recommended by the manufacturer of the vector and the 
expression host (Invitrogen, Calif.). Briefly, single colonies 
of BL21 (DE3) pLysS harboring the truncated plpE in 
pRSETA, were inoculated into appropriate volumes of LB 
broth with 50 µg/ml ampicillin and 34 µg/ml chlorampheni-
col. The culture was incubated at 37° C. until A600=0.5 was 
Another aspect of the present invention relates to methods 
useful to reduce the risk of BRD and shipping fever in cattle 65 
and prevent or attenuate biological transmission of the dis-
ease among cattle populations. attained at which time the synthesis of the recombinant pro-
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tein was induced by adding IPTG (1 mM final concentration) 
and the induction was continued for at least 3 hours. In order 
10 
to purify rPlpE, the culture was harvested and lysed by soni-
cation. The cellular debris was then removed by centrifuga-
tion and the recombinant protein was loaded onto an affinity 5 
colunm packed by Pro-Bond nickel-chelating resin that selec-
tively binds recombinant proteins with 6 histidine residues 
(His-Tag) at either the N- or carboxy-terminus. In this 
instance, the His-Tag is at the N-terminus. The recombinant 
protein bound to the resin was then eluted with either a low pH 10 
buffer or competition with imidazole. 
14. On day 0, three calves each were vaccinated subcutane-
ously with one of the following commercial vaccines: P. 
haemolytica Toxoid, BRSV-BVD-IBR-PI3 Vaccine (PYRA-
MID™ 4/PRESPONSE®; Fort Dodge Laboratories), P. 
haemolytica-multocida Bacterin-Toxoid (PULMO-
GUARD™ PH-M, Boehringer Ingelheim), P. haemolytica-
multocida-Salmonella typhimurium Bacterin-Toxoid (POLY-
BAC B® 1, Texas Vet Labs). Three calves were each 
vaccinated with 2 mg of an M. haemolytica outer membrane 
preparation in Freund's incomplete adjuvant or 10 9 CFU of 
live M. haemolytica. In addition, sera were analyzed from 
The purity of each preparation was determined by SDS-
PAGE followed by Coomassie stain and Western blot with 
murine anti-PlpE ascites fluid. 
1.3 .. Serology 
Antibodies to formalin-killed M. haemolytica whole bac-
terial cells (WC), to LKT, and to rPlpE were determined by 
enzyme-linked immunosorbent assay (ELISA). For WC 
preparation, M. haemolytica S 1 were prepared from a washed 
24 hour culture by suspending cells in 0.4% formalinized 
saline at a concentration determined spectrophotometrically 
to be 1.850 OD650 . LKT was prepared from supernatant from 
15 
three non-vaccinated calves that spontaneously serocon-
verted to M. haemolytica based on positive antibody 
responses to WC and LKT. 
The second vaccine experiment was a prospective study 
designed to follow the anti-PlpE antibodies for 42 days after 
a single dose of a commercial M. haemolytica vaccine or 
rPlpE. Thirty calves were divided equally among 6 groups 
and vaccinated subcutaneously once each on day 0 with PRE-
20 SPONSE®, P. haemolytica Bacterin-Toxoid (ONE SHOT™, 
Pfizer), an avirulent M. haemolytica culture (ONCE PMH®, 
Intervet), PULMO-GUARD™ PH-M, or 100 µg ofrPlpE in 
commercial adjuvant (Pfizer). Five unvaccinated calves 
served as controls. Sera were obtained on days 0, 7, 14, 21, 28, a 3-hour culture of M. haemolytica Sl grown in RPMI-1640 
medium at 37° C. in a shaking incubator. The LKT was 
partially purified by precipitation with 40-60% ammonium 
sulfate. The precipitate was resuspended in 3M guanidine 
containing 59 mM NaHPO4 and 100 mM NaCl. By SDS-
PAGE of the LKT preparation, one intensely staining band 
was identified at 105 kDa and confirmed to be LKT on a 30 
25 and 42, and antibodies to WC, LKT and PlpE were deter-
mined. 
1.6. Recombinant PlpE Immunogenicity Studies 
To determine if rPlpE was immunogenic, one calf each was 
vaccinated once with either 10, 50, or 100 µg ofrPlpE in a 
commercial proprietary adjuvant (Pfizer Inc, Lincoln, Nebr.). Western blot using an anti-LKT monoclonal antibody. Leu-
kotoxic activity was 10 4 LKT units per ml. The 2-keto-3-
deoxyoctonate concentration was 7 .5 µg per mg of protein. 
Wells of96-well microtiterplates were coated with WC at 
an optical density reading equivalent to 108 CFU of a 24-hour 
culture, with LKT at 50 ng per well, or with rPlpE at 50 ng per 
well. Sera were diluted in PBS-Tween 20 containing 1 % 
BSA. ELISA for detection of serum antibodies to PlpE was 
done in the first immunogenicity study using serum dilutions 
ranging from 1:400-1:819,200. Otherwise, sera were tested 
against various antigens at dilutions of 1 :800 for WC, 1: 1600 
for LKT, and 1: 1600 for rPlpE, which were in the linear range 
of established dilution curves. The extent of antibody binding 
was detected using a 1:400 dilution of horseradish peroxi-
dase-conjugated, affinity purified rabbit anti-bovine IgG 
(Kirkegaard & Perry Laboratories, Gaithersburg, Md.). Anti-
body responses are expressed as ng ofimmunoglobulin bind-
ing based on a set of IgG standards on each plate. 
1.4.Animals 
A total of 82 normal healthy beef calves (Hereford or 
Angus/Hereford cross) of mixed sex were used. The calves 
were weaned at around 6-8 months of age. All calves were 
vaccinated with 7-way Clostridial vaccine and leptospiral 
vaccine, and treated with anthelmintic 30 days prior to the 
study. The calves received free choice native grass hay 
supplemented with grain ration throughout the study. All 
animal studies were done following using protocols approved 
the University Institutional Animal Care and Use Committee 
(Protocol #182). 
1.5. Anti-PlpE Responses with M. haemolytica Vaccines 
To determine if vaccination of cattle with commercial or 
experimental M. haemolytica vaccines stimulate anti-PlpE 
antibodies, two studies were done. The first experiment was a 
retrospective study using sera from 18 cattle from previous 
vaccine studies. Serum antibodies to PlpE were determined 
on samples from the day of vaccination ( day 0) and from day 
One calf remained as a non-vaccinated control. Sera were 
obtained 21 days after vaccination and evaluated for end-
point antibody titers against rPlpE using serial 2-fold dilu-
35 tions. Twenty-four days after the initial vaccination, each calf 
and a non-vaccinated calf were transthoracically challenged 
with 5.0xl09 CFU oflive M. haemolytica from an overnight 
culture in accordance with established procedures. Four days 
later, calves were humanely killed, and lung lesion scores 
40 
determined on a 20-point scale. 
In a second cattle experiment, 6 cattle were vaccinated with 
100 µg of rPlpE in commercial adjuvant on day 0 and 6 calves 
remained as non-vaccinated controls. On day 21, all cattle 
were challenged intrathoracically with 1x109 CFU of virulent 
45 
M. haemolytica. Calves were humanely killed on day 25, and 
lung lesion scores determined. Antibody responses against 
rPlpE andM. haemolytica WC were determined on days 0, 7, 
14 and 21 after vaccination. 
In a third cattle experiment, PRESPONSE® was obtained 
50 
from the manufacturer, and 18 weanling beef steers were 
equally allocated among the following vaccine groups: Group 
1-PRESPONSE, Group 2-PRESPONSE+l00 µg PlpE, and 
Group 3-non-vaccinated. Cattle were vaccinated on day 0 
with 2 ml of PRESPONSE (manufacturer's recommended 
55 
dosage) or 2 ml of PRESPONSE mixed with 0.5 ml of PlpE 
(100 µg). Antibody responses to M. haemolytica WC, rPlpE 
or to LKT were determined by ELISA on days 0, 7, 15, and 
23. On day 24, cattle in Groups 1, 2, & 3 were challenged 
transthoracically with 3.0xl 09 CFU of M. haemolytica. Four 
60 
days later, calves were humanely killed, and lung lesion 
scores determined. 
1.7. Statistical Analysis 
Mean rectal temperatures, antibody responses and lesion 
scores among the various groups were compared by Students 
65 t tests. Mean rectal temperatures and antibody responses 
within groups were compared by paired t tests. Differences 
were considered significant when p<0.05. Linear regression 
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analyses were done to determine if there was a significant 
correlation between antibody response and lesion score. 
2. Results 
2.1. Recombinant PlpE Immunogenicity 
In the first immunogenicity experiment that determined 
end-point anti-rP!pE titers in response to various doses of 
rP!pE, serum from the non-vaccinated calf had an end-point 
antibody titer of 1 :400 against rP!pE. Sera from the 10, 50, 
and 100 µg vaccinates had titers of 1: 12,800, 1: 25,600, and 
1: 25,600, respectively. Intrathoracic challenge of those 
calves with virulent M. haemolytica resulted in a lesion score 
ofl 5.5 (20 maximum severity) for the non-vaccinated control 
calf. Lesion scores for the 10, 50, and 100 µg-vaccinates were 
4.5, 3.0, and 3.5 respectively. 
In the second immunogenicity experiment, vaccination 
with rP!pE on day O stimulate a significant increase in anti-
bodies to rP!pE and to M. haemolytica WC on day 7 (FIG. 1). 
Those responses continued to increase to a maximum on day 
12 
PULMOGUARD, and rP!pE). Peak antibody responses for 
ONE SHOT-vaccinated cattle were significantly greater than 
peak responses for ONCE PMH, PRESPONSE or rP!pE vac-
cinates. Although antibody responses to LKT increased after 
5 vaccination with each commercial vaccine, only the 
responses initiated by PULMOGUARD and ONE SHOT 
were significantly increased beginning on day 7 through day 
28. Anti-LKT antibodies did not increase for the rP!pE vac-
cinates. Peak anti-LKT antibody responses for PULMO-
10 GUARD-vaccinated cattle were significantly greater than 
peak responses for ONCE PMH, PRESPONSE or rPLpE 
vaccinates, whereas peak anti-LKT antibody responses for 
ONE SHOT-vaccinated cattle were significantly greater than 
peak responses for PRESPONSE vaccinates. 
15 
2.3. Augmentation of Commercial Vaccine with rP!pE 
Because vaccination with commercial M haemolytica vac-
cines stimulated low antibody responses to rP!pE, we inves-
tigated the augmentation of a commercial vaccine with rP!pE. 
20 and declined insignificantly on day 25, whereas antibodies 20 
to rP!pE and to WC failed to increase for the nonvaccinated 
calves. 
Vaccination with PRESPONSE stimulated a significant 
increase in anti-rP!pE antibodies on day 15. Those responses, 
however, were not significantly different than were antibody 
responses of the nonvaccinated control calves on days 7, 15, 
and 23 (FIG. 4 A-C). PRESPONSE-rP!pE vaccination stimu-Anti-LKT antibodies did not significantly increase for 
either the rP!pE-vaccinated or control groups ( data not 
shown). Mean lesion scores (standard deviation) after cha!- 25 
lenge were 7.0+3.8 for nonvaccinated controls and 4.1±3.0 
for the rP!pE vaccinates, a 41.4% reduction in lesion scores. 
Those differences were significant at the level of p=0.07. 
When data from the first experiment were combined with 
these data, the mean lesion score for nonvaccinated controls 30 
was 8.2±4.7 and mean lesion score for PlpE vaccinates was 
3.9±2.6 (p<0.05), a 52.1 % reduction in lesion scores. 
lated a significant increase in anti-rP!pE antibodies on days 7, 
15 and 23, and those responses were significantly higher than 
responses for the PRESPONSE-vaccinated or nonvaccinated 
control calves. Anti-WC and anti-LKT responses were sig-
nificantly increased on days 7 and 15 for the PRESPONSE-
and PRESPONSE-rP!pE vaccinates. Those responses were 
not significantly different between those groups, whereas 
they were significantly greater than were anti-WC and anti-
LKT antibody values for the nonvaccinated control group. 
Rectal temperatures were taken on the day of challenge 2.2. M. haemolytica Vaccines 
In the first vaccine experiment, vaccination of calves with 
commercial vaccines, M. haemolytica outer membranes, and 
live M. haemolytica resulted in a nonsignificant increase in 
antibodies to PlpE (FIG. 2). In contrast, natural exposure to 
M. haemolytica, as indicated by spontaneous seroconversion, 
resulted in a significant increase in anti-PlpE antibodies. All 
vaccine-induced responses and natural exposure were sub-
stantially less than the antibodies produced in a calf vacci-
nated with 100 µg of rP!pE in commercial adjuvant. There 
were no significant differences among the antibody responses 
to rP!pE on day 14 for any of the commercial vaccine, liveM. 
haemolytica vaccinated, or natural exposure groups. Anti-
body responses to M. haemolytica LKT and WC significantly 
increased for PULMOGUARD- and the live bacteria-vacci-
35 
(day 24) and for the next 3 days (FIG. 5). Rectal temperatures 
remained essentially normal for all cattle except for the non-
vaccinated Control group. In that group, rectal temperatures 
significantly increased on days 25 and 26, declining insignifi-
cantly on day 27. On days 26 and 27, mean rectal tempera-
40 tures for the nonvaccinated Control group were significantly 
greater than for either the PRESPONSE or PRESPONSE/ 
rP!pE groups. At necropsy, mean lung lesion scores were 
7.9±3.6 for nonvaccinated controls, 3.0±1.3 for PRE-
SPONSE-vaccinates (62.0% reduction in lesion score), and 
45 
1.1±0.9 for PRESPONSE/rP!pE vaccinates (86.1 % reduc-
tion in lesion scores). Differences between the PRESPONSE 
and Control and PRESPONSE/PlpE and Control lesion 
scores were significant. In addition, mean lesion score for the 
PRESPONSE/PlpE group was significantly lower than for nated and natural exposure calves, whereas vaccination with 
outer membranes stimulated a significant antibody response 50 
to WC and vaccination with POLY-BAC and PRESPONSE 
the PRESPONSE group. There was a significant correlation 
(r=-0.598, p<0.01) between high serum antibody responses 
to rP!pE at day 23 and low lesion scores. failed to stimulate significant antibody responses to either M. 
haemolytica antigen (data not shown). 3. Discussion 
The foregoing studies demonstrate that rP!pE is highly In the second vaccine experiment, vaccination of calves 
with one of four commercial M. haemolytica vaccines 
resulted in nonsignificant increases in antibodies to PlpE 
(FIG. 3). 
55 immunogenic for cattle and that vaccination with rP!pE can 
greatly enhance resistance against experimental challenge 
with the bacterium. The in vivo studies definitively indicate 
that anti-PlpE antibodies can contribute to host defense Vaccination of calves with 100 µg of rP!pE in commercial 
adjuvant stimulated a significant increase in antibody 
responses to PlpE by day 7. That response continued to 60 
increase until it peaked on day 21 after vaccination. Vaccina-
tion with each commercial vaccine and with rP!pE resulted in 
significant increases in antibodies to M. haemolytica WC by 
day 7 (ONE SHOT and PRESPONSE) and by day 14 (ONCE 
PMH, PULMOGUARD, and rP!pE) (FIG. 2). Those 
responses remained significantly increased through day 14 
(ONCE PMH and PRESPONSE) and day 42 (ONE SHOT, 
against M. haemolytica infection. 
Vaccination of cattle with commercial M. haemolytica vac-
cines, live M. haemolytica or outer membranes or after prior 
natural exposure stimulated low antibody responses to PlpE. 
For those vaccines, the rise in antibodies to rP!pE as measured 
on various days were not significant, and even those vaccines 
65 that stimulated high antibodies to M. haemolytica WC and 
LKT still stimulated low anti-rP!pE response. Commercial 
vaccine-induced anti-rP!pE antibody responses were sub-
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stantially lower than those stimulated by vaccination with 100 
µg of rPlpE in a commercial adjuvant. This was not unex-
pected, because commercial vaccines vary greatly in their 
composition in that some are composed of culture superna-
tants and bacterial cell components, others contain whole 5 
bacterial cells, and one is a live mutant. A somewhat surpris-
ing finding was that calves previously vaccinated with M. 
haemolytica outer membranes in Freund's incomplete adju-
vant had low antibody responses to rPlpE on day 14 (see 
Morton et al., supra). Therefore, although PlpE is a major 10 
outer membrane protein, its concentrations in commercial 
and experimental vaccines are most likely low and variable. 
In addition, the adjuvant used may play an important role in 
14 
LKT. The actual surface antigen of importance in stimulating 
protections is not known for sure; however, studies indicate 
that is it most likely outer membrane proteins and not capsular 
polysaccharide or lipopolysaccharide. Pandher et al. (Supra) 
demonstrated the presence of a PlpE-like protein in outer 
membrane of all M. haemolytica serotypes except serotype 
11, an uncommon isolate from shipping fever. There was 
some variation in molecular masses among the various pro-
teins. With the current findings, demonstrating immunoge-
nicity of rPlpE and augmentation of a commercial vaccine 
that stimulates anti-LKT antibodies, the previous demonstra-
tion of a PlpE-like protein in most serotypes and the at 
anti-LKT antibodies can neutralize LKT from other sero-
stimulating antibodies to PlpE. types, the addition of rPlpE to a commercial vaccine that 
15 stimulates anti-LKT antibodies will enhance cross serotype 
protection in shipping fever. 
Because commercial vaccines stimulated low antibodies to 
PlpE, we used rPlpE to augment the antibody response of a 
commercial vaccine, PRESPONSE, and demonstrated that 
PRESPONSE/PlpE stimulated greater protection against 
challenge than did PRESPONSE alone. Conlon et al. previ-
ously demonstrated that addition of recombinant LKT 20 
enhanced the efficacy of a culture supernatant vaccine and 
decreased clinical signs and pneumonic lesions. (Conlon J A, 
Shew en P E, Lo RY. Efficacy of recombinant leukotoxin in 
protection against pneumonic challenge with live Pasteurella 
EXAMPLE2 
Characterization of rPlpE epitopes 
Additional studies were undertaken to characterize sur-
face-exposed and immuologically important epitopes of 
rPlpE. 
haemolytica Al. Infect Immun 1991; 59:587-91) Therefore, 25 1. Materials and Methods 
addition of one or more recombinant proteins to a M. 
haemolytica vaccine could be used by animal health compa-
nies to provide better products for protection of cattle against 
shipping fever. 
In a recent survey, researchers found that of the M. 30 
haemolytica isolates from bovine respiratory disease from 
upper Midwestern United States were 60% Al, 26% A6 and 
7% A2 with the remaining isolates from A9, Al 1 and 
untypable strains.(Al-Ghamdi G M, Ames T R, Baker J C, 
Walker R, Chase C C, Frank G H, Maheswaran S K. Sero- 35 
typing of Mannheimia (Pasteurella) haemolytica isolates 
from the upper Midwest United States. J Vet Diagn Invest 
2000; 12: 576-8) In another study, 60% of M. haemolytica 
isolates from cattle in a Texas feedyard were Al, whereas 
40% were serotypes A2, A6, or AS (Purdy CW, Raleigh RH, 40 
Collins J K, Watts J L, Straus D C. Serotyping and enzyme 
characterization of Pasteurella haemolytica and Pasteurella 
multocida isolates recovered from pneumonic lungs of 
stressed feeder calves. Curr Microbial 1997; 34: 244-9). 
Therefore, although serotype 1 is the most common isolate 45 
from shipping fever, other serotypes play a role in the disease. 
Currently available M. haemolytica vaccines contain sero-
type 1 exclusively and therefore may or may not provide 
efficacious immunity against other serotypes. Cross serotype 
protection as stimulated by outer membrane vaccines or bac- 50 
terins is limited. It is known that antibodies against M. 
haemolytica serotype 1 LKT will cross neutralize the toxin 
prepared from other serotypes. Therefore, commercial vac-
cines that stimulate anti-LKT antibodies should provide some 
1.1 Construction and Purification of Truncated Forms of 
rPlpE 
Three additional rPlpE proteins carrying varying degrees 
of deletions were constructed in pET28 and purified accord-
ing to the method described above. The first of these was 
obtained by using plpBM-1 (5'-CTTGGATCCCAAGCA-
CAAAATGTT-3') (SEQ ID NO: 3), a primer that primes 84 
bp into the 5' end of plpE thus introducing a deletion of 28 
amino acids into the N-terminus end ofrPlpE (rPlpEAN28); 
and the second by plpBM-2 (5'-CCTGGATCCCAAGCA-
GAGGTTACT-3') (SEQ ID NO: 4), which primes 228 bp into 
the 5' end of plpE introducing a 76 amino acid deletion in the 
N-terminus of rPlpE (rPlpEAN76); and the third with 
plpBM-3 (5'-ATTGGATCCAATGCTGAACAACTC-3') 
(SEQ ID NO: 5) that primes 450 bp into 5' end of plpE 
introducing a deletion of 150 amino acids into the N-terminus 
in ofrPlpE (rPlpEANl 50). The reverse primer in all instances 
was plpEER, (5'-GACTGAATTCT-
TATTTTTTCTCGCTAACCATTA-3') (SEQ ID NO: 6). 
1.2. Production of Polyclonal Mouse Ascites 
cross protection against other serotypes. 
However, Conlon et al. (supra) demonstrated that vaccina-
tion with recombinant LKT alone failed to stimulate protec-
tion against experimental M. haemolytica challenge, and 
Purdy et al (Purdy C W, Straus D C, Struck D, Foster G S. 
Efficacy of Pasteurella haemolytica subunit antigens in a 60 
goat model of pasteurellosis.AmJ. Vet res 1993; 54:1637-47) 
found that vaccination of goats with LKT-impregnated agar 
beads stimulated incomplete immunity. Shewen and Wilkie 
(Shewen PE, Wilkie B N. Vaccination of calves with leuko-
toxic culture supernatantfrom Pasteurella haemolytica. Can J 65 
Vet Res 1988; 52:30-6) demonstrated that immunity to M. 
haemolytica was directed against both surface antigens and 
Three female, CFW mice were immunized 3 times with 50 
µg of complete or truncated rPlpE diluted by half in RIBI 
(Corixa Corp, Seattle, Wash.) adjuvant. The first immuniza-
tion was done subcutaneously (SC). Subsequent immuniza-
tions were done intraperitoneally (IP). A test-bleed was per-
formed and the serum screened for antibodies to rPlpE by 
ELISA. The response was moderate, so two additional immu-
nizations were performed IP. The mice were then injected 
55 with approximately 2x106 sarcoma cells (ATCC cat# TIB-
66). Between 7 and 10 days after sarcoma injection, the mice 
started producing ascites. Ascites fluid was removed from 
each mouse three times; mice were then euthanized by bar-
biturate overdose. 
1.3. Preparation of Affinity Columns and Purification of Anti-
PlpE Antibodies 
Purified rPlpE was coupled to NHS-activated 
SEPHAROSE™ 4 Fast Flow (Amersham Biosciences, 
Upsala, Sweden) according to the manufacturer's recommen-
dation. Briefly, 3-7 mg ofrPlpE in PBS was mixed with 2 ml 
bed volume of washed and equilibrated NHS-activated 
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SEPHAROSE™ 4 Fast Flow in an Econo Column (BioRad, 
Hercules, Calif.), incubated at 4 ° C. overnight at which time 
the non-reacted groups were blocked by 0.1 M Tris pH 8.0, 
and washed with alternating high and low pH buffers, Tris, pH 
8.0 and acetate buffer pH 4.0, respectively. 
Several affinity columns were prepared with rPlpE carrying 
varying degrees of truncation from the N-terminus. 
Anti-rPlpE antibodies against specific regions of PlpE 
were purified using the affinity columns described above. The 
Econo-Column with NHS-activated SEPHAROSE™ 
coupled to an rPlpE of interest was fitted with a Flow adaptor 
according to the recommendation of the manufacturer (Bio-
Rad, Hercules, Calif.). The affinity column was equilibrated 
by applying Dulbecco's Phosphate Buffered Saline (DPBS) 
at a flow rate of 1 ml/min. Hyperimmune serum produced by 
immunizing calves with the intact rPlpE was mixed with 
DPBS in a ratio of 1 to 10 and passed through Nalgene 0.45 
µm PES filters (Nalge, Rochester, N.Y.). The filtered serum 
was then applied to the equilibrated column via peristaltic 
pump at a flow rate of 1 ml/min. The flow thru was re-applied 
to the column several times to re-extract the serum by con-
necting the flow through to the reservoir of the initial serum. 
The column was then washed with DPBS. The complete 
removal of nonspecific proteins was determined with the help 
of the UV monitor attached to a chart recorder. Once there 
was no indication of nonspecific protein in the flow through, 
the specifically bound antibody was eluted with 100 mM 
Glycine Buffer (100 mM Glycine, 140 mM NaCl, pH 3.0) by 
collecting fractions in microfuge tubes containing 1/10 vol of 
16 
amino acid pentafluorophenyl esters. Peptides remained 
covalently attached to the cellulose membrane by the C-ter-
minus and have a free N-terminus. 
The peptide array was probed with anti-PlpE hyperim-
5 mune sera as follows. Prior to blotting, membranes with the 
custom spots were blocked with SuperB!ock® Dry Blend 
(Pierce, Rockford, Ill.) blocking buffer in TBS, pH 7.4. The 
membrane was then incubated in blocking buffer containing 
a primary antibody at a dilution of 1: 1000 to 1: 5000 for an 
10 hour. Following several washes with TBS, pH 7.4, supple-
mented with 0.05% Tween-20,0. 2% Triton®-X-100 (TB-
STT), the membrane was incubated in Superblock containing 
a goat anti-bovine or anti-mouse secondary antibody conju-
gated to Horse Radish Peroxidase (KPL, Gaithsburg, Md.) at 
15 dilutions 1:100,000to 1:200,000foronehour. The membrane 
was washed several times with TBS TT. The peptide array was 
incubated with SuperSignal® West Pico Chemiluminescent 
Substrate working solution (0.125 ml/cm2 ) for 5 minutes, 
placed in plastic membrane protector and exposed to a CL-X 
20 POSURE™ (Pierce, Rockford, Ill.) X-Ray film for varying 
durations of time. The X-Ray film was then developed in a 
Konica SRX-101A Medical Film Processor (Taiwan). The 
developedX-Ray film was scanned by Arcus 1200Agfa scan-
ner (Taiwan), and scanned images were analyzed using Gene 
25 Pix® Pro 4.0 (Axon Instruments, Union City, Calif.). Signal 
intensities were defined as median pixel intensity following 
subtraction of local median background signal. The peptide 
array was stripped with RESTORE™ Western Blot Stripping 
Buffer (Pierce, Rockford, Ill.) according to the procedure 
30 recommended by the manufacturer before it was probed with 
a different anti-PlpE antibody. This was repeated several 
times with anti-PlpE antibodies obtained from different 
sources or purified in varieties of ways. 
1 M Tris-HCl, pH 8.0. The absorbance of each fraction was 
determined at 280 nm. Those fractions that had a reading at 
least 2-3 times the background were pooled and dialyzed 
overnightagainstDPBS at4° C. ina Slide-A-Lyzer® Dialysis 
Cassette (Pierce, Rockford, Ill.). The concentration of affinity 
35 
purified antibody was determined with BCA Protein Assay 
Kit (Pierce, Rockford, Ill.). More specific antibodies against 
rPlpE with 28, 76 and 150 amino acids deletions on their 
N-termini, rPlpEllN28 (pSAC63), rPlpEllN76 (pSAC64) and 
rPlpEllNl 50 (pSAC65), respectively, were purified as 
~~~ ~ 
2. Results 
2.1. Epitope Mapping of PlpE 
The determination of the epitope map of PlpE was 
attempted in two steps. The first approach involved the local-
ization of the general area of immunogenic or immunodomi-
nant epitopes by deleting specific regions of PlpE from both 
the N-Terminus and C-Terminus by PCR with the help of 
Antibodies against regions of PlpE that are exposed on the 
surfaces of M. haemolytica cells were purified as described by 
Turbyfill et al., (1998). Briefly, intact M haemolytica cells 
from the late log phase were incubated with hyperimmune 
bovine sera immunized by rPlpE or anti-PlpE mouse ascites 
diluted in PBS on ice for 2-4 hr with gentle agitation. The cells 
were spun down and washed several times with PBS. The 
antibodies bound to the surface were eluted by resuspending 
andagitatingthecellsin0.lMG!ycine, 140mMNaCl,pH3.0 
for at least 30 minutes. The cells were centrifuged at 13,000x 
g, and the eluted antibodies were collected in the supernatant 
which was neutralized immediately by adding ½o volume of 
1 M Tris, pH 8.0. 
1.4. Epitope Mapping of PlpE by Peptide Array (Pepscan) 
A peptide array comprising a total of 109 overlapping 
13-mer peptides with 3 amino acid offsets was custom made 
by Sigma-Genosys LP (The Woodlands, Tex.). Briefly the 
synthesis of peptides was performed on cellulose membranes 
in which hydroxyl functions of a commercially available filter 
paper are derivatized with 9-fluorenylmethoxycarbonyl-B-
alanine (Fmoc-B-Ala) with subsequent removal of the Fmoc 
group. The synthesis areas were defined by spotting a Fmoc-
B-alanine-pentafluorophenyl ester solution to distinct areas 
on the membrane. Blocking the remaining amino functions 
between spots provided discrete reaction sites on the mem-
brane for further standard solid phase peptide synthesis using 
specific primers. A total of 6 plasmid constructs carrying the 
plpE gene with varying degrees of deletions were made. The 
cloning of three of these constructs that carry deletions from 
45 the N-termini of PlpE, (pSAC63, pSAC64, and pSAC65) is 
described above. Three additional plasmids viz., pSAC30, 
pSAC31, and pSAC32 that carry 106(rPlpEAC106), 96(rPl-
pEAC96) and 86(rPlpEAC86) amino acid deletions on the 
C-terminus of PlpE, respectively, were designed and con-
50 structed. The reverse primers used to introduce these dele-
tions on the 3' end of the plpE gene in the latter constructs 
were HNplp-1 (5'-GATAAGCTTTTACCGTGCG-
GCAAATTC-3') (SEQ ID NO: 7), Hnplp-2(5'-AAAAAGC-
TITTATTTAATTTCTACATC-3') (SEQ ID NO: 8), and 
55 HNplp-3 (5'-TTTAAGCTTTTATATACTTCCTTGAGC-3') 
(SEQ ID NO: 9), respectively, and a forward primerplpEBH, 
(5'-GTCAGGATCCTGCGGAGGAAGCGGTAGC-3') 
(SEQ ID NO: 
10). Amplimers were cut with BamHI and HindIII and 
60 cloned into pET28 or pRSETA cut with the same enzymes. 
Following confirmation of the identity of putative clones by 
both restriction analysis and sequencing, plasmids from true 
clones were introduced into BL21 (DE3) by transformation 
where the truncated forms of PlpE were overexpressed and 
65 purified according to the protocol described earlier. The 6 
truncated forms of rPlpE and the intact form were separated 
on a 12.5% SDS-PAGE for Western analysis. Hyperimmune 
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serum from calves immunized with the intact rPlpE was used 
as primary antibodies and goat anti-bovine alkaline Phos-
phatase conjugated antibodies as secondary antibodies. Den-
sitometric analysis of the respective bands in a Western blot in 
which the same amount of the recombinant proteins were 5 
loaded onto an SDS-PAGE and probed with hyperimmune 
serum from a calf that was immunized with rPlpE clearly 
showed that there are significant differences amongst recom-
binant proteins carrying deletions in the intensity of their 
reaction to the hyperimmune serum. Accordingly there is no 10 
difference in the intensity of binding between rPlpE and 
mutants with the deletions from the C-terminus viz., 
pSAC30, pSAC31, and pSAC32 that carry 106 
(rPlpEllC106), 96 (rPlpEllC96) and 86 (rPlpEllC86) amino 
acid deletions on the C-terminus of PlpE, respectively. The 15 
binding capacity of mutants carrying deletions on their N-ter-
mini decreases with increasing deletions. There is no appre-
ciable difference between rPlpE and pSAC63 (rPlpEllN28) 
with 28 amino acid deletions on the N-terminus. The reactiv-
with rPlpE was used to probe the stripped peptide array, the 
same set of peptides mentioned above were identified once 
again confirming the binding capacity of the above indicated 
stretches of amino acids along PlpE. On the other hand, when 
sera from calves that were given live M haemolytica were 
used to probe the peptide array, epitope 2 was the only one 
that was picked up. According to the manufacturers of the 
custom spots, non-specific binding of the antibody-enzyme 
conjugate may occur to peptides that contain combinations of 
basic amino acids. When goat anti-bovine-HRP, the second-
ary antibody used in this project, was used to probe the spots, 
epitopes 1, 3, 4, 7, and 8 were picked up. The same sets of 
epitopes were identified when the array was probed with 
rabbit anti-bovine-HRP, showing putative epitopes 1, 3, 4, 7, 
and 8 were not true epitopes. In order to identify spots that 
would non-specifically bind bovine immunoglobulins, serum 
from colostrum deprived new born calf was used to pro be the 
array. Interestingly, in addition to the putative epitopes iden-
tified by the secondary antibody-enzyme conjugates, i.e. 1, 3, 
4, 7, and 8, epitopes 5 and 6 exhibited reactivity to bovine 
immunoglobulins. Epitope 2 was the only one that did not 
react to both the serum from the colostrum deprived calf and 
secondary antibody-enzyme conjugate showing that this 
epitope is the only one responsible for inducing the specific 
immune response when calves were either vaccinated with 
rPlpE or M. haemolytica. 
ity of pSAC64 (rPlpEllN76), which carries a deletion of 76 20 
amino acids on the N-terminus, drops to 63%, which is a 37% 
loss in signal intensity, when compared to rPlpE. Further 
deletion into the N-terminus as seen in pSAC65 
(rPlpEllN150) reduces the binding capacity of the truncated 
proteins by 60%. These findings clearly suggest that the 25 
region between residues 28 and 76 from the N-terminus of 
PlpE carries a stretch of amino acids with possible epitope(s) 
that may be responsible for invoking the immune response 
elicited when rPlpE is used as a vaccine. A closer examination of epitope 2 shows that this is part of 
2.2. Fine Mapping ofEpitopes on PlpE 
Putative antigenic regions in PlpE were identified by using 
the MACVECTOR™ 7 .0 software that employed algorithms 
such as antigenic index, hydrophilicity and surface probabil-
ity. However, the identification of epitopes was done with a 
peptide array comprising 109 overlapping 13-mer peptides 
that were synthesized by the chemistry described earlier. The 
peptides were covalently bound to derivatized cellulose 
membrane by the C-terminus and have a free N-terminus. 
Anti-PlpE hyperimmune antibodies purified by any number 
of the methods described earlier were used to probe the pep-
tide array. The custom spots were stripped and probed several 
times. When bovine antibody against surface exposed com-
ponents of PlpE that was affinity purified with intact M. 
haemolytica cells was used to probe the peptide array a total 
of 8 distinct regions (El-8) were identified (FIG. 6). Epitope 
1 (PNHPKPVLVPKTQNNL) (SEQ ID NO: 11) spans 3 pep-
tides; epitope 2 (QNASQAQNAPQAQNAPQAQNAPQVE-
NAPQAQNAPQVENAPQAE) (SEQ ID NO: 12), 11 pep-
tides; epitope 3 (GSFDKIGSVKLNK) (SEQ ID NO: 13), 3 
peptides; epitope 4 (KLGTPPKFDKVSGKKIIEE) (SEQ ID 
NO: 14), 6 peptides; epitope 5 (LIRRSDDLFYGYY) (SEQ 
ID NO: 15), 3 peptides; epitope 6 (ADKFSQYFVVYDE) 
(SEQ ID NO: 16), 3 peptides; epitope 7 (NISDKL-
TATYRKK) (SEQ ID NO: 17), 2 peptides; and epitope 8 
(PHTKEFAARISKL) (SEQ ID NO: 18). Approximately the 
same set of epitopes, albeit with decreasing intensities, were 
picked up when whole serum obtained from cows with a 
naturally high anti-PlpE antibody titer that were also chal-
lenged with live M haemolytica was used. The signal inten-
sities of all of the epitopes with the exception of epitope 2 
were much lesser in this blot than in the earlier. The purifica-
tion of IgG from the latter serum with Protein G affinity 
colunms did not alter the above result in that exactly the same 
putative epitopes were identified suggesting that IgG was the 
class of immunoglobulins involved in this immune response. 
When whole hyperimmune serum from calves immunized 
30 the region identified as having 8 imperfect repeats of 
hexapeptides (Pandher et. al., 1998). The 11 peptides (#13 
through 23) identified here as epitope 2 comprise the last 4 
residues of the rd repeat described by Pandher et al., (1998) 
and the rest of the repeats i.e., repeats 3 through 8 with the 
35 
exception of the 1st hexapeptide. A feature of these 11 pep-
tides is the lack of uniformity in their binding capacity as 
evidenced by the variation in their signal intensities. Peptides 
#15, 17, and 19 exhibit the highest signal intensities followed 
40 by #s 21 and 23. The first five residues of the N-termini of 
these peptides are QNAPQ (SEQ ID NO: 33) with the excep-
tion of #21 in which the first glutamine is replaced by 
glutamate. It is worthwhile noting that both glutamine and 
asparagine are positively charged, with hydrophobicity index 
45 of -0.91 and-0.92, respectively. The remaining 6 peptides in 
epitope 2 have praline at their N-termini instead of glutamine 
and this may account for their relatively lower signal intensity 
in the peptide array. The relatively high signal intensities 
exhibited by peptides 15, 17, and 19 may reflect the manner in 
50 which these epitopes are presented to the immune system 
under natural condition on the surfaces of M. haemolytica 
cells and the inherent immunogenic nature of these stretches 
of amino acids. The fact that epitope 2 contains a significant 
number of pralines at defined intervals which are usually 
55 indicators of turns, has an unusually high number of very 
basic residues such as glutamine, asparagine and glutamate 
which are hydrophilic, with high surface probability and 8 
repeats are features that are usually associated with regions of 
60 
protein that are associated with being immunogenic. More-
over, computer analysis of the deduced amino acid sequence 
of epitope 2 with algorithms such as Parker's antigenicity, 
Kyte/Doolittle hydrophilicity, surface probability and Chou 
Fasman D structure indices show that the stretch of amino 
65 acids has a moderately high antigenicity, fairly hydrophilic, 
contains fairly high number of amino acids with very high 
surface probability and is characterized by series of turns 
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associated with helices and sheets, respectively, all of which 
are strong indicators of a region that is potentially highly 
immunogenic. 
EXAMPLE3 
Construction of PlpE Chimeras 
3 .1 Construction of Chimeras 
The importance of antibodies to the major surface-exposed 
and immunogenic lipoprotein PlpE in stimulating immunity 
20 
(SAC86, SAC87, SAC88, SAC89, & SAC91) that comprise 
the immunodominant epitopes of PlpE (R2) and LKT were 
constructed (Table 1 ). DNA fragments that encode for the 55 
amino acids that make up the R2 region (TPNHPKPVLVP-
5 KTQNNLQAQNVPQAQ-
NASQAQNAPQAQNAPQAQNAPQVENAPQA; SEQ ID 





to M. haemolytica has thus been demonstrated. In particular, DSRNVLVAPTSM; SEQ ID NO: 21) and flanking regions of 
it has been found that the major immunogenic epitopes of LKT were amplified by polymerase chain reaction (PCR) 
rPlpE are located in the N-terminal region of the protein, usingforwardprimerscontainingBamHiandreverseprimers 
encoded (approximately) by nucleotides 231-407. In addi- 15 containing Bg!II. Each PCR product was cut with both 
tion, promising results in stimulating immunity to M. BamHI and Bg!II and sequentially ligated into pET41 and 
haemolytica had also been obtained with the exotoxin and pET28 that were digested with BamHI in the following man-
virulence factor leukotoxin (LKT). In particular, a "minimal" ner. First the BamHI/BglII leukotoxin neutralizing epitope is 
gene fragment encoding carboxy-terminal amino acids 809- ligated into vectors linearized with BamHI. The orientation of 
939 ofLKT (mLKTA) elicits a considerable leukotoxin neu- 20 insertion and integrity of the constructs were confirmed by 
tralizing-antibody response in rabbits (Lainson, 1996). both restriction enzyme analysis and sequencing. Then these 
The next stage of vaccine development involved the con- constructs were linearized with BamHI and ligated to 
struction of chimeric proteins which included major epitopes BamHI/BglII R2 fragments. This was repeated until the 
of both of these two proteins, and tests of the ability of the desired copies of each epitope were successfully cloned in the 
chimeric proteins to elicit a protective immune response 25 right orientation and order. Recombinant plasmids that were 
against M. haemolytica. Significant goals of the experiments derived from pET 41 are pSAC86 and pSAC87 that have GST 
described in this section were to develop chimeric plpe/LKTA leader sequences encode for the chimeric proteins SAC86 and 
genes, purify chimeric PldE/LKT proteins, study their immu- SAC87. Similarly, plasmids that were derived from pET28 
nogenicity, and develop chimeric vaccines that are efficacious were pSAC88 and pSAC89 and they encode for the chimeric 
against M. haemolytica challenge. 30 proteins SAC88 and SAC89. The amino acid sequences of the 
Five exemplary novel chimeras were constructed in which chimeric proteins SAC86, SAC87, SAC88, SAC89 and 
single or multiple copies of antigenic regions of rPlpE and SAC91 and the nucleotide sequences that encode them are 
LKT were present, with or without a glutathione-S-trans- given in FIGS. lOA-B, llA-B, 12A-B, 13A-B and 14A-B, 
ferase (GST) leader sequence. The constructs contain a major respectively. 
surface-exposed epitope of PlpE, epitope 2, ( designated "R2" 35 Each recombinant plasmid was introduced into the E. coli 
in this Example, and "E2 in Examples 1-2) andmLKTA. The expression host, BL21(DE3)pLysS, by transformation and 
amino acid sequence ofR2 (SEQ ID NO: 19) and the nucleic recombinant chimeric proteins expressed and purified. Trans-
acid sequence encoding R2 (SEQ ID NO: 20) are shown in formants carrying the recombinant plasmids were grown in 
FIGS. 7A and B, respectively. The amino acid sequence of LB broth supplemented with 30 µg ofkanamycin/ml and 34 
mLKTA (SEQ ID NO: 21) and the nucleic acid sequence 40 µg of chloramphenicol/ml . Expression was induced by add-
encoding mLKTA (SEQ ID NO: 22) are shown in FIGS. SA ing isopropyl-~-D-galactopyranoside (IPTG), and cells were 
and B, respectively. In addition, five chimeric proteins were harvested by centrifugation at 10,000xg at 4 ° C., resuspended 
constructed which contained various combinations ofR2 and in binding buffer (6M urea, 500 mM NaCl, 20 mM Tris-HCl, 
mLKTA, separated by spacer peptides. The compositions of 5 mM imidazole [pH 7 .9]) containing protease-inhibitor 
the five chimeras are given in Table 1 and schematic repre- 45 cocktail III (Calbiochem, La Jolla, Calif.), and lysed in an 
sentations of the plasmids encoding the chimeras are shown Aminco French pressure cell (SLM Instruments, Inc., Roch-
in FIGS. 9A-F. ester, N.Y.). Cellular debris was removed by centrifugation, 
TABLE 1 
Summary of the recombinant chimeric plasmids 
Plasmid Designation Description of Insert Name of Recombinant Protein 
pSAC86 G-R2-LKTA SAC86 
pSAC87 G-2(R2-LKTA) SAC87 
pSAC88 R2-LKTA SAC88 
pSAC89 2(R2-LKTA) SAC89 
pSAC91 G-S-R2-S-LKTA-S SAC91 
G = GST leader peptide 
R2 = immunodominant epitope of PlpE 
and the supernatant containing the recombinant protein was 
clarified by filtration. Recombinant chimeric protein was 
50 purified by binding to and elution from a His•Bind® column 
55 
(Novagen). Fractions containing the recombinant protein 
were pooled. The identity, purity, and integrity of purified 
proteins was determined by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) followed by 
Coomassie staining and Western blotting with murine anti-
PlpE polyclonal ascites and murine anti-leukotoxin mono-
clonal antibodies. 
3.2 Testing of Chimeric Proteins in a Vaccine Trials 
LKTA = section of the C terminus ofLKTA that includes the leukotoxinneutralizing epitope 60 
S = GGGGS spacer peptide (SEQ ID NO: 35) 
The PlpE/LKTA chimeric proteins were tested for immu-
nogenicity in CD-1 mice using Titermax® TM adjuvant. The 
design of the experiment is presented in Table 2. Six groups of 
18 mice per group were used. Groups 1-5 were further divided 
into 3 subgroups of 6 mice per subgroup. Mice in each sub-
The plasmids encoding the chimeric proteins were devel-
oped and the chimeric proteins were isolated, purified and 
characterized as follows: 
Construction of Recombinant Plasmids and Expression and 
Purification of Chimeric Proteins. Five chimeric proteins 
65 group were given 25, 50 or 75 µg of a chimeric protein 
intraperitoneally on day 0. The Group 6 mice received only 
adjuvant. Three mice per subgroup were bled at day 28, and 
US 7,794,734 B2 
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the final 3 mice per subgroup were bled on day 42. Antibody 
responses to PlpE and LKTA were determined by ELISA 
TABLE2 
22 
combined with lyophilized LKT to allow neutralization of the 
LKT by anti-LKT antibodies. BL-3 cells were suspended to a 
concentration of 2.5x106 cells/ml and 50 µl was added to 
each neutralization reaction. The cell mixture was incubated 
5 and the soluble MTT was added to each sample. MTT is 
Experimental design of murine chimeric protein immunization study 
Plasmid Name of Recombinant 
Group# Designation Description of Insert Protein 
pSAC86 G-R2-LKTA SAC86 
2 pSAC87 G-2(R2-LKTA) SAC87 
3 pSAC88 R2-LKTA SAC88 
4 pSAC89 2(R2-LKTA) SAC89 
5 pSAC91 G-S-R2-S-LKTA-S SAC91 
6 Control Titermax® n/a 
adjuvant only 
G = GST leader peptide 
R2 = immunodominant epitope of PlpE 
LktA = section of the C terminus ofLktA that includes the leukotoxin neutralizing epitope 
S = spacer peptide 
10 
15 
converted by viable cells to an insoluble precipitate, which is 
then dissolved and read spectrophotometrically. The amount 
of precipitate formed relates to the amount of LKT neutral-
ization that has occurred. LKT neutralizing mouse mono-
clonal antibody (MM601) was used as a positive control and 
colostrum-deprived calf serum (CDCS) was used as a nega-
tive control. As can be seen, LKT neutralization activity of 
anti-chimeric immune sera ranges from 45% to 142% of that 
ofMM601. 
FIG. 19 depicts bactericidal activity of murine anti-SAC-
89 hyper-immune sera obtained as the result of administering 
either 25 µg of SAC89 (89-25) or 50 µg of SAC89 (89-50). 
Tests were carried out in the presence of a suitable source of 
complement. Tests were carried out in the presence of a 
The endpoint titration data when rPlpE is used as a ligand 
is shown in FIG. 15A-C. (The nomenclature in the figures 
designates the protein and its concentration used in the vac-
cine, e.g. "8825" or "88-25" indicates mice vaccinated with 
25 µg ofSAC88.)A comparison of the immune responses to 
rPlpE indicates that SAC 86, 87, 88 and 89 are all highly 
immunogenic. However, this is not the case with SAC91, the 
chimera that includes spacer peptides. As can be seen, the 
chimeras that contain 2 copies of the epitopes from the two 
proteins (i.e. SAC87 and SAC89) were better immunogens, 
as evidenced by the high titer of the anti-rPlpE antibodies in 
the sera of mice that were vaccinated with these two recom-
binant proteins. 
20 suitable source of complement. Complement-mediated kill-
ing assay was done as we have previously described (Ayalew, 
S., A. W. Confer, and E. R. Blackwood. 2004. Characteriza-
tion of immunodominant and potentially protective epitopes 
ofMannheimia haemolytica serotype 1 outermembranelipo-
25 protein PlpE. Infect Immun 72:7265-7274.). Briefly, M. 
haemolytica cells were grown in BHI broth and decapsulated 
in lxPBS at 41 ° C. The cells were resuspended to an 
O.D. 600=0.500 and then diluted to 1: 1000 in PBS for use in 
the assay. The mouse sera were heat treated at 56° C. to 
Antibody titers against mlktA is shown in FIG. 15D-F. As 
can be seen, SAC 86, SAC87, SAC88 and SAC89 elicit sig-
nificantly higher antibody titers to this immunodominant 
epitope than does SAC91. 
30 inactivate existing complement and used as the antibody 
sources. Colostrum-deprived calf serum was used as the 
source of complement in the assay. The antibodies, bovine 
complement, and decapsulated M. haemolytica cells were 
mixed and plated on BHIA Blood plates at TO and T 30 after 
35 incubation at 3 7° C. Growth was determined by counting the 
number of colonies present after 15-16 hours of incubation at 
37° C. and 5% CO2 and the percent killing was calculated 
with the formula: [(T0 growth-T30 growth)/T0 growth]x 
100% 
The results of a summary of antibody responses to the 
chimeric proteins as determined by a single dilution ELISA 
are presented in FIG. 16. As can be seen, according to this 
assay, SAC89 protein ( containing two R2 and two mLKTA 40 
antigens) was the best overall antigen. 
The response of mice to vaccination with the chimeric 
proteins was also quantified with Western blots, coupled with 
densitometric analysis of the bands. The results are given in 
FIGS.17AandB, withFIG.17Ashowingtheresultsobtained 45 
for LKT and FIG. 17B showing the results obtained for PlpE. 
As can be seen, the SAC89 protein again appears to elicit the 
best overall response to both antigens. 
FIG. 18 depicts LKT neutralization activity of murine anti-
chimeric immune sera at a dilution of 1: 16 as determined by 50 
MTT assay. A colorimetric microtitration assay was adapted 
to quantify the cytotoxicity of LKT to bovine neutrophils 
used as target cells (Vega, M. V., S. K. Maheswaran, J. R. 
Leininger, and T. R. Ames. 1987. Adaptation ofa colorimetric 
microtitration assay for quantifying Pasteurella haemolytica 55 
Al leukotoxin and antileukotoxin. Am J Vet Res 48:1559-
1564). The viability ofLKT-treated target cells was detected 
by use of methylthiazole tetrazolium (MTT) assay. The MTT 
assay is based on measuring the activity of living cells via 
mitochondrial dehydrogenases that cleave the tetrazolium 60 
ring of MTT, yielding purple formazan crystals which are 
insoluble in aqueous solutions. The crystals are dissolved in 
acidified isopropanol and measured spectrophotometrically. 
The amount of formazan formed was quantified by use of an 
ELISA plate reader and is directly proportional to the number 65 
of viable target cells, thus allowing its adaptation for detect-
ing LKT-neutralization antibody titers. The mouse sera were 
The results showed that the serum bactericidal activity of 
mouse anti-SAC89 hyper-immune sera is as potent as serum 
from a calf that was vaccinated with intact rPlpE. 
EXAMPLE4 
Vaccination With SAC89 and Challenge WithMannheimia 
haemolytica Experimental design and results. Fifteen 
recently weaned Angus cross steers were purchased. Eight 
were vaccinated subcutaneously with PBS in Emulsigen-P 
adjuvant on day 0, whereas 7 received 100 µg of SAC89 plus 
adjuvant subcutaneously in the neck. The vaccine was 
repeated on day 28. Antibody responses against SAC89, leu-
kotoxin, recombinant PlpE, and whole bacterial cells were 
significantly increased by day 14 after vaccination (FIG. 20 
A-D). A decline in antibodies followed with a significantly 
higher response after revaccination on day 28. During the 
course of the study, calf#48 caught its head in a feed bunk and 
broke its neck. It was thus removed from the study. 
On day 42, cattle were challenged transthoracically with 
5x109 CFU of live, virulent Mannheinia haemolytica Al 
Oklahoma strain (Panciera & Corstvet, Am J Vet Res. 1984 
December; 45 (12:2532-7). Calf#25 died within3 days after 
challenge due to severe pneumonia and terminal septicemia 
and was given the maximum score of 20 (Panciera et al. Am 
J Vet Res 1984 December; 45 (12);2538-42). Four days after 
challenge, cattle were humanely killed and lungs evaluated 
for lesion scores on a 20 point scale (0 being no lesion and 20 
US 7,794,734 B2 
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being maximum). There was a significant reduction (69.9%, 
p <0.02) in lesion scores for SAC89 vaccinates compared to 
PBS/Adjuvant vaccinates (Table 3). 
TABLE3 
Lesion scores after vaccination with SAC89 or PBS 
CalfNo. Vaccine Lesion Score 
8 PBS/ADJ 1.5 
21 PBS/ADJ 7.5 
22 PBS/ADJ 7.5 
25 PBS/ADJ 20 
29 PBS/ADJ 13 
31 PBS/ADJ 8.5 
41 PBS/ADJ 5 
42 PBS/ADJ 1.5 
48 PBS/ADJ Deceased* 
Mean± SD 8.06 ± 6.13 
3 SAC89/ADJ 1.5 
7 SAC89/ADJ 1.5 
12 SAC89/ADJ 0 
23 SAC89/ADJ 2 
30 SAC89/ADJ 2 
32 SAC89/ADJ 5.5 
39 SAC89/ADJ 4.5 
Mean± SD 2.43 ± 1.9 
(69.9% reduction in lesion scores) 
*Calf died from an accident and was removed from the study. 
P < 0.02 between vaccinates and controls 
This example shows that vaccination of cattle with a 
recombinant chimeric protein comprising PlpE-LKT of M. 
haemolytica provides significant protection against challenge 
with virulentM. Haemolytica. In addition, the vaccine stimu-
lates antibodies to M. haemolytica LKT, whole cells, outer 
membrane lipoprotein PlpE and to the chimeric protein itself. 
24 
In addition, other short sequences may serve as "spacer+ 
peptides, for example, between R2 peptide sequences in a 
polypeptide that comprises more than one R2 sequence, and/ 
or between R2 and mLKT sequences in a polypeptide that 
5 comprises one or more of R2 or mLKT, or both. In one 
embodiment, the spacer peptide is Arg-Ser (i.e. "RS"). How-
ever, those of skill in the art will recognize that other spacer 
peptides may also be used in the practice of the invention, 
including but not limited to Gly-Gly-Gly-Ser (i.e. GGGS, 
10 SEQ ID NO: 34), and others, so long as the spacer peptides 
allow exposure of the antigenic epitopes to the immune sys-
tem a mamier that results in an immune response. 
The nucleotide sequences used to generate the antigens 
may be inserted into any of a wide variety of expression 
15 vectors by a variety of procedures. Such procedures and oth-
ers are deemed to be known by those skilled in the art. Suit-
able vectors include chromosomal, nonchromosomal and 
synthetic DNA sequences; e. g., derivatives of SV 40; bacte-
rial plasmids; phage DNAs ; yeast plasmids; vectors derived 
20 from combinations of plasmids and phage DNAs, viral DNA 
such as baculovirus, vaccinia, adenovirus, fowl pox virus, 
pseudorabies, etc. The appropriate DNA sequence must be 
operatively linked in the vector to an appropriate expression 
control sequence(s) (promoter) to direct mRNA synthesis. As 
25 representative examples of such promoters, there may be 
mentioned LTR or SV 40 promoter, the E. coli lac or trp, the 
phage lambda PL promoter and other promoters known to 
control expression of genes in prokaryotic and eukaryotic 
cells or their viruses. The expression vector also includes a 
30 non-coding sequence for a ribosome binding site for transla-
tion initiation and a transcription terminator. The vector may 
also include appropriate sequences for amplifying expres-
s10n. 
The vector containing an appropriate sequence, as well as 
35 an appropriate promoter or control sequence, may be 
employed to transform an appropriate host to permit the host 
to express the protein. Examples of host organisms and cells 
include bacterial strains (e.g., E.coli, Pseudomonas, Bacil-
lus, Salmonella, etc.), fungi (e. g., yeasts and other fungi), 
Accordingly, it can be appreciated that subunits derived 
from PlpE, and especially epitope 2 (i.e. R2), are useful as 
well in the inventive vaccine compositions and methodolo-
gies. The inclusion of such region(s) enhances the host 
immune response directed against relevant immunoprotec-
tive epitopes. It accordingly can be appreciated that the inven-
tive vaccines utilize as distinct antigenic components rPlpE or 
subunits thereof capable of eliciting an antibody or other 
immune response against M. haemolytica. As a result, the 
invention encompasses proteins which may be the full length 
antigen, antigen fragment, antigen derivative or a fusion prod-
uct of such antigen, antigen fragment or antigen derivative 
with another protein. In particular, chimeric proteins com-
prising antigenic regions of rPlpE and LKT are effective in 
eliciting a protective immune response against M. 
haemolytica. Proteins included within the present invention 50 
include those depicted in the Sequence Listing as well as 
mutants of said sequences capable of eliciting an antibody or 
other immune response which recognizes an epitope(s) of 
such amino acid sequences. In general, the polypeptides that 
represent the proteins of the invention will have at least from 55 
about 60 to 70% identity with the sequences presented herein, 
and preferably about 70 to about 80% identity, and more 
preferably about 80 to 90% identity, and most preferably 
about 90-95 or 95-100% identity. 
40 animal or plant hosts (e.g., mouse, swine or animal and 
human tissue cells). The selection of the host is deemed to be 
within the scope of those skilled in the art. 
As previously mentioned, it is also understood that the 
appropriate sequence present in the vector when introduced 
45 into a host may express part or only a portion of the protein 
which is encoded within the noted terminology, it being suf-
ficient that the expressed protein be capable of eliciting an 
antibody or other immune response which recognizes an 
epitope(s) of the listed amino acid sequences. 
The isolated polypeptides expressed by the host trans-
formed by the vector may be harvested by methods which will 
occur to those skilled in the art and used in a vaccine for 
providing an enhanced immune response against infection 
with M. haemolytica. Vaccine preparation is easily accom-
plished using well known methods and techniques. An 
enhanced immune response is manifest by protection against 
infection or a decrease in severity of infection, which may be 
reflected in body temperature and antibody titers as described 
above. 
The host expressing the antigen may itself be used to 
deliver antigen to non-human animals, by introducing killed 
or viable host cells that are capable of propagating in the 
animal. Direct incorporation of the nucleotide sequences into 
host cells may also be used to introduce the sequences into 
In addition, the chimeric proteins of the invention may also 60 
include a leader sequence. In one embodiment, the leader 
sequence is glutathione-S-transferase (GST), the sequence of 
which is known and readily available (see, for example, U.S. 
Pat. No. 6,368,584, the contents of which is hereby incorpo-
rated by reference). However, those of skill in the art will 
recognize that other leader sequences exist which are also 
suitable for use in the invention. 
65 animal cells for expression of antigen in vivo. 
Vaccine preparations are combined with physiologically 
acceptable carriers to form vaccines. The carrier employed in 
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conjunction with vaccine may be any one of a wide variety of 
carriers. As representative examples of suitable carriers, there 
may be mentioned mineral oil, synthetic polymers, etc. Car-
riers for vaccines are well known in the art and the selection 
of a suitable carrier is deemed to be within the scope of those 5 
skilled in the art. The selection of a suitable carrier is also 
R2 as represented by SEQ ID NO: 19, and the exemplary 
immunodominant region or epitope of LKT is mLKT as 
represented by SEQ ID NO: 21. In addition, those of skill in 
the art will recognize that several modifications of these 
sequences can be made for any of several purposes, without 
compromising the ability of the chimeric protein to elicit a 
suitable immune response. For example, conservative amino 
acid substitutions can be tolerated. Conservative amino acid 
substitution can be defined as recognized by those of skill in 
dependent upon the manner in which the vaccine is to be 
administered. The preferred physiologically acceptable car-
rier is an adjuvant. Preferably, the inventive vaccine formu-
lation is set to contain about 10-100, and preferably about 
100, micrograms of recombinant antigens in commercially 
available adjuvant (Pfizer). Similar quantities of recombinant 
antigens would be used if added to another commercial vac-
cine formulation. 
Examples of adjuvants that may be used in the practice of 
the invention include but are not limited to: aluminum 
hydroxide gel-based adjuvants, saponin-based adjuvants, 
block co-polymer-based adjuvants, water-in-oil adjuvants, 
and oil-in-water adjuvants. Specific examples include but are 
not limited to Freund's incomplete adjuvant, TiterMax®, 
Emulsigen®-P, Xtend II, Xtend SP, SUPERIMM®, and RIBI 
adjuvant. 
The vaccines may be administered by a variety of routes 
including intravenously, intraperitoneally, intramuscularly, 
and subcutaneously. The preferred route of administration is 
subcutaneous. Alternatively, the vaccine may be administered 
intranasally or orally. The vaccine can be administered in a 
single dose or multiple doses until a protective effect is 
achieved. 
Those of skill in the art will further recognize that in order 
to function as a "vaccine", inoculation with a protein of the 
invention ( e.g. a chimeric protein) may, on the one hand, offer 
full protection from the development of symptoms associated 
with infection by M. haemolytica (i.e. so-called symptoms of 
"shipping fever"). However, a vaccine preparation can be 
valuable even if symptoms are not totally prevented, but are 
merely attenuated. Further, the vaccine preparation may be 
used prophylactically prior to suspected exposure to the etio-
logical agent of the disease, or after exposure, or even after 
some symptoms of disease have appeared. Benefit from the 
immune stimulating effects of the vaccine preparation that is 
administered may accrue even after the onset of infection. 
10 the art, for example, according to the BLOSUM62 matrix, 
described by Henikoff and Henikoff (S. Hemikoff and J. G. 
Henikoff, Proc. Natl. Acad. Sci. USA 89, 10915-10919, 
1992). In addition, the deletion of a small number (e.g. 
15 
approximately 1-10) amino acids from the amino or carboxy 
terminus or within the sequence, or the substitution of various 
modified or non-natural amino acids, addition of histidine 
tags, etc. may also be tolerated without compromising the 
ability of the immunodominant region or epitope to function 
20 
in the practice of the present invention. Such modifications 
may be carried out for any of a variety of purposes, including 
but not limited to increase or decrease solubility of the 
polypeptide, to prevent or aid digestion by proteases, to facili-
tate isolation and purification of the protein (polypeptide), 
25 
etc. Further, various labels may be included to facilitate track-
ing of the protein ( e.g. introduction ofa tryptophan residue, or 
introduction of a chemical label). In general, polypeptides 
that are encompassed by the invention will have at least from 
about 60 to 70% identity with the sequences presented herein, 
30 
and preferably about 70 to about 80% identity, and more 
preferably about 80 to 90% identity, and most preferably 
about 90-95 or even about 95-100% identity, e.g. to R2, or to 
mLKTA individually. All such sequence variants are intended 
to be encompassed by the invention, so long as the resultant 
35 
peptide sequence retains the activity of the parent peptide 
sequence. Those of skill in the art are well acquainted with 
methods by which one can test and compare the immunoge-
nicity of different peptides/polypeptides and their effective-
ness in eliciting an immune response, and their ability to 
40 
provide protection to challenge with a disease-causing entity. 
Exemplary methods are fully described in the Examples sec-
tion of this application. 
The vaccines of the invention may be administered alone as 
the sole agent for combating M. haemolytica infection. Alter-
natively, the vaccine preparations may be administered in 45 
concert with other agents such as vaccine preparations utiliz-
ing other M. haemolytica proteins or antigens, several com-
mercial varieties of which are known. 
In some embodiments, the chimeric protein contains mul-
tiple copies of the immunodominant epitopes. In one embodi-
ment, the chimera contains two copies each of R2 and 
mLKTA. However, this need not be the case. Higher numbers 
of copies are also contemplated ( e.g. 3 or even many more). 
Any number of copies may be utilized, so long as the con-
struct that encodes the chimera and the chimera itself are able According to the invention, chimeric proteins which 
include one or more immunodominant epitopes ofrecombi- 50 
nant PlpE in combination with one or more immunodominant 
epitopes ofLKT, are provided as vaccinating agents. Those of 
skill in the art will recognize that several terms are used in the 
to be successfully manipulated and processed in the labora-
tory and during vaccine preparation. Further, the number of 
copies of each moiety (R2 and mLKTA) need not be equal, 
i.e. a chimera may contain one copy of R2 and two or more 
copies of mLKTA, or vice versa. In addition, one or more 
immunodominant epitopes from other species or strains can 
also be incorporated into the chimera, e.g. from other M. 
haemolytica. 
In addition, the arrangement (i.e. order or position) of the 
immunodominant regions within the chimeric protein may 
vary. For example, the protein may contain two R2 regions in 
tandem, followed by two mLKTA regions in tandem. Alter-
natively, a protein may contain alternate regions, e.g. 
R2-mLKTA-R2-mLKTA, etc. Any such combination is con-
sidered to be within the scope of the invention, so long as the 
art to describe peptide and/or polypeptide sequences that 
elicit an immune response, and that there is sometimes over- 55 
lap or inconsistency within the art with respect to the catego-
rization of such sequences. Herein, the term "immunodomi-
nant epitope" or "immunodominant region" is intended to 
refer to regions (i.e. segments or portions) of a protein from a 
pathogenic organism that, when administered to a mammal, 60 
are capable of inducing a protective immune response to the 
organism in the mammal. Generally, but not always, such 
immundominant regions or epitopes are highly immunogenic 
when tested according to methods that are known to those of 
skill in the art, such as those described herein. 65 resulting chimeric protein elicits a suitable and useful 
immune response to M. haemolytica, e.g. a sufficient 
response to prevent or attenuate symptoms of disease that 
In a preferred embodiment of the invention, the exemplary 
immunodominant region or epitope of PlpE that is utilized is 
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would likely occur in the vaccinated mammal, if the mammal 
had not been vaccinated by a preparation containing the chi-
meric protein. 
Likewise, while exemplary DNA acid sequences that 
encoding chimeric proteins are presented herein, those of 
skill in the art will recognize that the nucleic acids of the 
invention are not limited to those specific sequences, or even 
In addition to the administration of a proteinaceous vaccine 
preparation, the invention also contemplates administration 
of a nucleic acid encoding the antigenic protein. In this 
embodiment, the protein ( e.g. a chimeric protein) is translated 
5 within the vaccinated host. Those of skill in the art are aware 
of the many systems for delivery of nucleic acid (e.g. DNA) 
vaccines, including liposomal preparations, various viral vec-
tors, (e.g. adenovirus, hepatitis, etc.), and the like. to DNA. RNA encoding the chimeric proteins is also within 
the scope of the invention, as are modifications to the encod-
ing sequences that can be tolerated without vitiating the effi- 10 
cacy of the polypeptide that is produced. For example, due to 
the redundancy of the genetic code, many sequences other 
than those that are presented may be used in the practice of the 
invention. Other variants of the nucleic acid sequences may 
In view of the above, it will be seen that the several objec-
tives of the invention are achieved and other advantageous 
results attained. As various changes could be made in the 
above sequences, antigens, etc. without departing from the 
scope of the invention, it is intended that all matter contained 
in the above description or shown in the accompanying draw-
ings shall be interpreted as illustrative and not in a limiting 
sense. 
be introduced, for example, in order to stabilize the nucleic 15 
acid, to facilitate isolation or tracking of the DNA ( e.g. vari-
ous labels), etc. In general, nucleic acid sequences that are 
included in the present invention will be about 60 to 70% 
homologous to the sequences presented herein, and prefer-
ably about 70 to about 80% homologous, and more preferably 20 
about 80 to 90% homologous, and most preferably about 
90-95 or 95-100% homologous, e.g. to R2, or to mLKTA 
encoding sequences. 
While the invention has been described with a certain 
degree of particularity, it is understood that the invention is 
not limited to the embodiment( s) set for herein for purposes of 
exemplification, but is to be limited only by the scope of the 
attached claim or claims, including the full range of equiva-
lency to which each element thereof is entitled. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 35 
<210> SEQ ID NO 1 
<211> LENGTH, 1310 
<212> TYPE, DNA 
<213> ORGANISM, Mannheimia haemolytic a 
<400> SEQUENCE, 1 
agggctaatc tactacagcc ccaaaaattt tcataaggga aacgtttacg taaaactcct 60 
cagaccactc attcttattt tatataaaaa atgtgataga cttctcgcag tttcgtttta 120 
tatatttaag gaataactaa gtgaaattca ataaaaaatt aattttaaca tttgctgcaa 180 
ccttagtttt aagtgcttgc ggaggaagcg gtagcggagg ttcgtcttca acaccgaatc 240 
accccaaacc agtactagta ccaaaaacac aaaataatct tcaagcacaa aatgttcctc 300 
aggcacaaaa tgcctctcag gcacaaaatg cccctcaggc acaaaatgct cctcaggcac 360 
aaaatgctcc tcaggtggaa aatgctcctc aggcacaaaa tgctcctcag gtagaaaatg 420 
ctcctcaagc agaggttact ccgcctgtac cacagccaca atcacaaaaa attgacggtt 480 
cttttgataa aattggttca gtaaaactca ataaagaggc tcaaactctt gagcttagta 540 
gattcacttt ggtggataaa ttaggcacac caccgaagtt tgataaagta agcggtaaaa 600 
aaattattga agaaaaagat tttctcgtat taaatttgtc tgatattaat gctgaacaac 660 
tctctggcga ttttcttatt cgccgtagcg atgatctatt ctatggctac tatcacgata 720 
caaatggcaa aaatcttgtc gatgctgccg ataaattcag tcaatatttt gtcgtgtatg 780 
atgagaaacg ggtaaatgat aatatctctg ataaattaac agcaacttac cgtaaaaaag 840 
aaggctttgt atatggttca aatccacata ctaaagaatt tgccgcacgg atcagcaaat 900 
tgggggatgt agaaattaaa tttgaaaatg gtcaagctca aggaagtata aaagacgaaa 960 
aagatggaaa tgctgagatc tttactatta aaggtgatac aaaacagtta gagattaccc 1020 
caacggaaag taaccgaatc attatagcaa ttttagacca aaatcaaaaa agctatactc 1080 
caggaatgga aaaagcaatt atggaaacta agtttattga ttcaaaggct ggtaattccg 1140 
US 7,794,734 B2 
29 
-continued 
accaaaaata cttaatcggt gaagcaaaaa gcgataactg gcaagcaata atggttagcg 
agaaaaaata aagttatctt ttgctaaaaa ctgaaataaa aaggctgagt ccgggtaata 
tcggcctcag tcttttaaat tgtagaaaat catctgtaga agatcaaacc 
<210> SEQ ID NO 2 
<211> LENGTH, 337 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 2 
Cys Gly Gly Ser Gly Ser Gly Gly Ser Ser Ser Thr Pro Asn His Pro 
1 5 10 15 
Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn Leu Gln Ala Gln Asn 
20 25 30 
Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro Gln Ala 
35 40 45 
Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro 
50 55 60 
Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro Gln Ala Glu Val 
65 70 75 80 
Thr Pro Pro Val Pro Gln Pro Gln Ser Gln Lys Ile Asp Gly Ser Phe 
85 90 95 
Asp Lys Ile Gly Ser Val Lys Leu Asn Lys Glu Ala Gln Thr Leu Glu 
100 105 110 
Leu Ser Arg Phe Thr Leu Val Asp Lys Leu Gly Thr Pro Pro Lys Phe 
115 120 125 
Asp Lys Val Ser Gly Lys Lys Ile Ile Glu Glu Lys Asp Phe Leu Val 
130 135 140 
Leu Asn Leu Ser Asp Ile Asn Ala Glu Gln Leu Ser Gly Asp Phe Leu 
145 150 155 160 
Ile Arg Arg Ser Asp Asp Leu Phe Tyr Gly Tyr Tyr His Asp Thr Asn 
165 170 175 
Gly Lys Asn Leu Val Asp Ala Ala Asp Lys Phe Ser Gln Tyr Phe Val 
180 185 190 
Val Tyr Asp Glu Lys Arg Val Asn Asp Asn Ile Ser Asp Lys Leu Thr 
195 200 205 
Ala Thr Tyr Arg Lys Lys Glu Gly Phe Val Tyr Gly Ser Asn Pro His 
210 215 220 
Thr Lys Glu Phe Ala Ala Arg Ile Ser Lys Leu Gly Asp Val Glu Ile 
225 230 235 240 
Lys Phe Glu Asn Gly Gln Ala Gln Gly Ser Ile Lys Asp Glu Lys Asp 
245 250 255 
Gly Asn Ala Glu Ile Phe Thr Ile Lys Gly Asp Thr Lys Gln Leu Glu 
260 265 270 
Ile Thr Pro Thr Glu Ser Asn Arg Ile Ile Ile Ala Ile Leu Asp Gln 
275 280 285 
Asn Gln Lys Ser Tyr Thr Pro Gly Met Glu Lys Ala Ile Met Glu Thr 
290 295 300 
Lys Phe Ile Asp Ser Lys Ala Gly Asn Ser Asp Gln Lys Tyr Leu Ile 
305 310 315 320 
Gly Glu Ala Lys Ser Asp Asn Trp Gln Ala Ile Met Val Ser Glu Lys 






<210> SEQ ID NO 3 
<211> LENGTH, 24 
<212> TYPE, DNA 
31 
<213> ORGANISM, Artificial 
<220> FEATURE, 
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<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 3 
cttggatccc aagcacaaaa tgtt 
<210> SEQ ID NO 4 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 4 
cctggatccc aagcagaggt tact 
<210> SEQ ID NO 5 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 5 
attggatcca atgctgaaca actc 
<210> SEQ ID NO 6 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 6 
gactgaattc ttattttttc tcgctaacca tta 
<210> SEQ ID NO 7 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 7 
gataagcttt taccgtgcgg caaattc 
<210> SEQ ID NO 8 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 8 
aaaaagcttt tatttaattt ctacatc 
<210> SEQ ID NO 9 
<211> LENGTH, 27 
<212> TYPE, DNA 
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<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 9 
tttaagcttt tatatacttc cttgagc 
<210> SEQ ID NO 10 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 10 
gtcaggatcc tgcggaggaa gcggtagc 
<210> SEQ ID NO 11 
<211> LENGTH, 16 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 11 
Pro Asn His Pro Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn Leu 
1 5 10 15 
<210> SEQ ID NO 12 
<211> LENGTH, 43 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 12 
Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro 
1 5 10 15 
Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro Gln Ala Gln Asn 
20 25 30 
Ala Pro Gln Val Glu Asn Ala Pro Gln Ala Glu 
35 40 
<210> SEQ ID NO 13 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 13 
Gly Ser Phe Asp Lys Ile Gly Ser Val Lys Leu Asn Lys 
1 5 10 
<210> SEQ ID NO 14 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 14 
Lys Leu Gly Thr Pro Pro Lys Phe Asp Lys Val Ser Gly Lys Lys Ile 
1 5 10 15 
Ile Glu Glu 
<210> SEQ ID NO 15 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 15 





<210> SEQ ID NO 16 
<211> LENGTH, 13 
<212> TYPE, PRT 
35 
10 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 16 
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Ala Asp Lys Phe Ser Gln Tyr Phe Val Val Tyr Asp Glu 
1 5 10 
<210> SEQ ID NO 17 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 17 
Asn Ile Ser Asp Lys Leu Thr Ala Thr Tyr Arg Lys Lys 
1 5 10 
<210> SEQ ID NO 18 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 18 
Pro His Thr Lys Glu Phe Ala Ala Arg Ile Ser Lys Leu 
1 5 10 
<210> SEQ ID NO 19 
<211> LENGTH, 55 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 19 
Thr Pro Asn His Pro Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn 
1 5 10 15 
Leu Gln Ala Gln Asn Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln 
20 25 30 
Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln 
35 40 45 
Val Glu Asn Ala Pro Gln Ala 
50 55 
<210> SEQ ID NO 20 
<211> LENGTH, 165 
<212> TYPE, DNA 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 20 
acaccgaatc accccaaacc agtactagta ccaaaaacac aaaataatct tcaagcacaa 60 
aatgttcctc aggcacaaaa tgcctctcag gcacaaaatg cccctcaggc acaaaatgct 120 
cctcaggcac aaaatgctcc tcaggtggaa aatgctcctc aggca 165 
<210> SEQ ID NO 21 
<211> LENGTH, 131 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 21 
Ser Asp Ser Asn Leu Lys Asp Leu Thr Phe Glu Lys Val Lys His Asn 
1 5 10 15 
36 
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Leu Val Ile Thr Asn Ser Lys Lys Glu Lys Val Thr Ile Gln Asn Trp 
20 25 30 
Phe Arg Glu Ala Asp Phe Ala Lys Glu Val Pro Asn Tyr Lys Ala Thr 
35 40 45 
Lys Asp Glu Lys Ile Glu Glu Ile Ile Gly Gln Asn Gly Glu Arg Ile 
50 55 60 
Thr Ser Lys Gln Val Asp Asp Leu Ile Ala Lys Gly Asn Gly Lys Ile 
65 70 75 80 
Thr Gln Asp Glu Leu Ser Lys Val Val Asp Asn Tyr Glu Leu Leu Lys 
85 90 95 
His Ser Lys Asn Val Thr Asn Ser Leu Asp Lys Leu Ile Ser Ser Val 
100 105 110 
Ser Ala Phe Thr Ser Ser Asn Asp Ser Arg Asn Val Leu Val Ala Pro 
115 120 125 
Thr Ser Met 
130 
<210> SEQ ID NO 22 
<211> LENGTH, 393 
<212> TYPE, DNA 
<213> ORGANISM, Mannheimia haemolytica 








<210> SEQ ID NO 23 
<211> LENGTH, 486 








<213> ORGANISM: Mannheimia haemolytica 













Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro 
1 5 10 15 
Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 
20 25 30 
Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 
35 40 45 
Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 
50 55 60 
Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn 
65 70 75 80 
Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu 
85 90 95 
Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 
100 105 110 
Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 
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Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 
130 135 140 
Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 
145 150 155 160 
Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 
165 170 175 
Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 
180 185 190 
Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 
195 200 205 
Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Gly Ser Thr Ser 
210 215 220 
Gly Ser Gly His His His His His His Ser Ala Gly Leu Val Pro Arg 
225 230 235 240 
Gly Ser Thr Ala Ile Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu 
245 250 255 
Arg Gln His Met Asp Ser Pro Asp Leu Gly Thr Gly Gly Gly Ser Gly 
260 265 270 
Asp Asp Asp Asp Lys Ser Pro Met Gly Tyr Arg Gly Ser Thr Pro Asn 
275 280 285 
His Pro Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn Leu Gln Ala 
290 295 300 
Gln Asn Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro 
305 310 315 320 
Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn 
325 330 335 
Ala Pro Gln Ala Arg Ser Ser Asp Ser Asn Leu Lys Asp Leu Thr Phe 
340 345 350 
Glu Lys Val Lys His Asn Leu Val Ile Thr Asn Ser Lys Lys Glu Lys 
355 360 365 
Val Thr Ile Gln Asn Trp Phe Arg Glu Ala Asp Phe Ala Lys Glu Val 
370 375 380 
Pro Asn Tyr Lys Ala Thr Lys Asp Glu Lys Ile Glu Glu Ile Ile Gly 
385 390 395 400 
Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val Asp Asp Leu Ile Ala 
405 410 415 
Lys Gly Asn Gly Lys Ile Thr Gln Asp Glu Leu Ser Lys Val Val Asp 
420 425 430 
Asn Tyr Glu Leu Leu Lys His Ser Lys Asn Val Thr Asn Ser Leu Asp 
435 440 445 
Lys Leu Ile Ser Ser Val Ser Ala Phe Thr Ser Ser Asn Asp Ser Arg 
450 455 460 
Asn Val Leu Val Ala Pro Thr Ser Met Arg Ser Glu Phe Glu Leu Arg 
465 470 475 480 
Arg Gln Ala Leu Ile Asn 
485 
<210> SEQ ID NO 24 
<211> LENGTH, 1459 
<212> TYPE, DNA 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 24 
tgtcccctat actaggttat tggaaaatta agggccttgt gcaacccact cgacttcttt 60 
40 
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tggaatatct tgaagaaaaa tatgaagagc atttgtatga gcgcgatgaa ggtgataaat 
ggcgaaacaa aaagtttgaa ttgggtttgg agtttcccaa tcttccttat tatattgatg 
gtgatgttaa attaacacag tctatggcca tcatacgtta tatagctgac aagcacaaca 
tgttgggtgg ttgtccaaaa gagcgtgcag agatttcaat gcttgaagga gcggttttgg 
atattagata cggtgtttcg agaattgcat atagtaaaga ctttgaaact ctcaaagttg 
attttcttag caagctacct gaaatgctga aaatgttcga agatcgttta tgtcataaaa 
catatttaaa tggtgatcat gtaacccatc ctgacttcat gttgtatgac gctcttgatg 
ttgttttata catggaccca atgtgcctgg atgcgttccc aaaattagtt tgttttaaaa 
aacgtattga agctatccca caaattgata agtacttgaa atccagcaag tatatagcat 
ggcctttgca gggctggcaa gccacgtttg gtggtggcga ccatcctcca aaatcggatg 
gttcaactag tggttctggt catcaccatc accatcactc cgcgggtctg gtgccacgcg 
gtagtactgc aattggtatg aaagaaaccg ctgctgctaa attcgaacgc cagcacatgg 
acagcccaga tctgggtacc ggtggtggct ccggtgatga cgacgacaag agtcccatgg 
gatatcgggg atccacaccg aatcacccca aaccagtact agtaccaaaa acacaaaata 
atcttcaagc acaaaatgtt cctcaggcac aaaatgcctc tcaggcacaa aatgcccctc 
aggcacaaaa tgctcctcag gcacaaaatg ctcctcaggt ggaaaatgct cctcaggcaa 
gatcctctga ttcgaactta aaagatttaa catttgaaaa agttaaacat aatcttgtca 
tcacgaatag caaaaaagag aaagtgacca ttcaaaactg gttccgagag gctgattttg 
ctaaagaagt gcctaattat aaagcaacta aagatgagaa aatcgaagaa atcatcggtc 
aaaatggcga gcggatcacc tcaaagcaag ttgatgatct tatcgcaaaa ggtaacggca 
aaattaccca agatgagcta tcaaaagttg ttgataacta tgaattgctc aaacatagca 
aaaatgtgac aaacagctta gataagttaa tctcatctgt aagtgcattt acctcgtcta 
atgattcgag aaatgtatta gtggctccaa cttcaatgag atccgaattc gagctccgtc 
gacaagcttt aattaatta 
<210> SEQ ID NO 25 
<211> LENGTH, 676 
<212> TYPE, PRT 
<213> ORGANISM: Mannaheimia haemolytica 
<400> SEQUENCE, 25 
Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro 
1 5 10 15 
Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 
20 25 30 
Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 
35 40 45 
Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 
50 55 60 
Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn 
65 70 75 80 
Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu 
85 90 95 
Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 
100 105 110 
Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 
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Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 
130 135 140 
Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 
145 150 155 160 
Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 
165 170 175 
Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 
180 185 190 
Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 
195 200 205 
Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Gly Ser Thr Ser 
210 215 220 
Gly Ser Gly His His His His His His Ser Ala Gly Leu Val Pro Arg 
225 230 235 240 
Gly Ser Thr Ala Ile Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu 
245 250 255 
Arg Gln His Met Asp Ser Pro Asp Leu Gly Thr Gly Gly Gly Ser Gly 
260 265 270 
Asp Asp Asp Asp Lys Ser Pro Met Gly Tyr Arg Gly Ser Thr Pro Asn 
275 280 285 
His Pro Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn Leu Gln Ala 
290 295 300 
Gln Asn Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro 
305 310 315 320 
Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn 
325 330 335 
Ala Pro Gln Ala Arg Ser Ser Asp Ser Asn Leu Lys Asp Leu Thr Phe 
340 345 350 
Glu Lys Val Lys His Asn Leu Val Ile Thr Asn Ser Lys Lys Glu Lys 
355 360 365 
Val Thr Ile Gln Asn Trp Phe Arg Glu Ala Asp Phe Ala Lys Glu Val 
370 375 380 
Pro Asn Tyr Lys Ala Thr Lys Asp Glu Lys Ile Glu Glu Ile Ile Gly 
385 390 395 400 
Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val Asp Asp Leu Ile Ala 
405 410 415 
Lys Gly Asn Gly Lys Ile Thr Gln Asp Glu Leu Ser Lys Val Val Asp 
420 425 430 
Asn Tyr Glu Leu Leu Lys His Ser Lys Asn Val Thr Asn Ser Leu Asp 
435 440 445 
Lys Leu Ile Ser Ser Val Ser Ala Phe Thr Ser Ser Asn Asp Ser Arg 
450 455 460 
Asn Val Leu Val Ala Pro Thr Ser Met Arg Ser Thr Pro Asn His Pro 
465 470 475 480 
Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn Leu Gln Ala Gln Asn 
485 490 495 
Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro Gln Ala 
500 505 510 
Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro 
515 520 525 
Gln Ala Arg Ser Ser Asp Ser Asn Leu Lys Asp Leu Thr Phe Glu Lys 
530 535 540 
44 
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Val Lys His Asn Leu Val Ile Thr Asn Ser Lys Lys Glu Lys Val Thr 
545 550 555 560 
Ile Gln Asn Trp Phe Arg Glu Ala Asp Phe Ala Lys Glu Val Pro Asn 
565 570 575 
Tyr Lys Ala Thr Lys Asp Glu Lys Ile Glu Glu Ile Ile Gly Gln Asn 
580 585 590 
Gly Glu Arg Ile Thr Ser Lys Gln Val Asp Asp Leu Ile Ala Lys Gly 
595 600 605 
Asn Gly Lys Ile Thr Gln Asp Glu Leu Ser Lys Val Val Asp Asn Tyr 
610 615 620 
Glu Leu Leu Lys His Ser Lys Asn Val Thr Asn Ser Leu Asp Lys Leu 
625 630 635 640 
Ile Ser Ser Val Ser Ala Phe Thr Ser Ser Asn Asp Ser Arg Asn Val 
645 650 655 
Leu Val Ala Pro Thr Ser Met Arg Ser Glu Phe Glu Leu Arg Arg Gln 
660 665 670 
Ala Leu Ile Asn 
675 
<210> SEQ ID NO 26 
<211> LENGTH, 1459 
<212> TYPE, DNA 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 26 
tgtcccctat actaggttat tggaaaatta agggccttgt gcaacccact cgacttcttt 
tggaatatct tgaagaaaaa tatgaagagc atttgtatga gcgcgatgaa ggtgataaat 
ggcgaaacaa aaagtttgaa ttgggtttgg agtttcccaa tcttccttat tatattgatg 
gtgatgttaa attaacacag tctatggcca tcatacgtta tatagctgac aagcacaaca 
tgttgggtgg ttgtccaaaa gagcgtgcag agatttcaat gcttgaagga gcggttttgg 
atattagata cggtgtttcg agaattgcat atagtaaaga ctttgaaact ctcaaagttg 
attttcttag caagctacct gaaatgctga aaatgttcga agatcgttta tgtcataaaa 
catatttaaa tggtgatcat gtaacccatc ctgacttcat gttgtatgac gctcttgatg 
ttgttttata catggaccca atgtgcctgg atgcgttccc aaaattagtt tgttttaaaa 
aacgtattga agctatccca caaattgata agtacttgaa atccagcaag tatatagcat 
ggcctttgca gggctggcaa gccacgtttg gtggtggcga ccatcctcca aaatcggatg 
gttcaactag tggttctggt catcaccatc accatcactc cgcgggtctg gtgccacgcg 
gtagtactgc aattggtatg aaagaaaccg ctgctgctaa attcgaacgc cagcacatgg 
acagcccaga tctgggtacc ggtggtggct ccggtgatga cgacgacaag agtcccatgg 
gatatcgggg atccacaccg aatcacccca aaccagtact agtaccaaaa acacaaaata 
atcttcaagc acaaaatgtt cctcaggcac aaaatgcctc tcaggcacaa aatgcccctc 
aggcacaaaa tgctcctcag gcacaaaatg ctcctcaggt ggaaaatgct cctcaggcaa 
gatcctctga ttcgaactta aaagatttaa catttgaaaa agttaaacat aatcttgtca 
tcacgaatag caaaaaagag aaagtgacca ttcaaaactg gttccgagag gctgattttg 
ctaaagaagt gcctaattat aaagcaacta aagatgagaa aatcgaagaa atcatcggtc 
aaaatggcga gcggatcacc tcaaagcaag ttgatgatct tatcgcaaaa ggtaacggca 
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aaaatgtgac aaacagctta gataagttaa tctcatctgt aagtgcattt acctcgtcta 
atgattcgag aaatgtatta gtggctccaa cttcaatgag atccgaattc gagctccgtc 
gacaagcttt aattaatta 
<210> SEQ ID NO 27 
<211> LENGTH, 235 
<212> TYPE, PRT 
<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 27 
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 
1 5 10 15 
Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 
20 25 30 
Gly Ser Thr Pro Asn His Pro Lys Pro Val Leu Val Pro Lys Thr Gln 
35 40 45 
Asn Asn Leu Gln Ala Gln Asn Val Pro Gln Ala Gln Asn Ala Ser Gln 
50 55 60 
Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala 
65 70 75 80 
Pro Gln Val Glu Asn Ala Pro Gln Ala Arg Ser Ser Asp Ser Asn Leu 
85 90 95 
Lys Asp Leu Thr Phe Glu Lys Val Lys His Asn Leu Val Ile Thr Asn 
100 105 110 
Ser Lys Lys Glu Lys Val Thr Ile Gln Asn Trp Phe Arg Glu Ala Asp 
115 120 125 
Phe Ala Lys Glu Val Pro Asn Tyr Lys Ala Thr Lys Asp Glu Lys Ile 
130 135 140 
Glu Glu Ile Ile Gly Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val 
145 150 155 160 
Asp Asp Leu Ile Ala Lys Gly Asn Gly Lys Ile Thr Gln Asp Glu Leu 
165 170 175 
Ser Lys Val Val Asp Asn Tyr Glu Leu Leu Lys His Ser Lys Asn Val 
180 185 190 
Thr Asn Ser Leu Asp Lys Leu Ile Ser Ser Val Ser Ala Phe Thr Ser 
195 200 205 
Ser Asn Asp Ser Arg Asn Val Leu Val Ala Pro Thr Ser Met Arg Ser 
210 215 220 
Glu Phe Glu Leu Arg Arg Gln Ala Leu Ile Asn 
225 230 235 
<210> SEQ ID NO 28 
<211> LENGTH, 1278 
<212> TYPE, DNA 
<213> ORGANISM, Mannheimia haemolytica 
<400> SEQUENCE, 28 
atgggcagca gccatcatca tcatcatcac agcagcggcc 
atggctagca tgactggtgg acagcaaatg ggtcgcggat 
ccagtactag taccaaaaac acaaaataat cttcaagcac 
aatgcctctc aggcacaaaa tgcccctcag gcacaaaatg 
cctcaggtgg aaaatgctcc tcaggcaaga tcctctgatt 







































<210> SEQ ID NO 29 
<211> LENGTH, 425 

















<213> ORGANISM: Mannheimia haemolytica 
<400> SEQUENCE, 29 

















Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 
1 5 10 15 
Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 
20 25 30 
Gly Ser Thr Pro Asn His Pro Lys Pro Val Leu Val Pro Lys Thr Gln 
35 40 45 
Asn Asn Leu Gln Ala Gln Asn Val Pro Gln Ala Gln Asn Ala Ser Gln 
50 55 60 
Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala 
65 70 75 80 
Pro Gln Val Glu Asn Ala Pro Gln Ala Arg Ser Ser Asp Ser Asn Leu 
85 90 95 
Lys Asp Leu Thr Phe Glu Lys Val Lys His Asn Leu Val Ile Thr Asn 
100 105 110 
Ser Lys Lys Glu Lys Val Thr Ile Gln Asn Trp Phe Arg Glu Ala Asp 
115 120 125 
Phe Ala Lys Glu Val Pro Asn Tyr Lys Ala Thr Lys Asp Glu Lys Ile 
130 135 140 
Glu Glu Ile Ile Gly Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val 
145 150 155 160 
Asp Asp Leu Ile Ala Lys Gly Asn Gly Lys Ile Thr Gln Asp Glu Leu 
165 170 175 
Ser Lys Val Val Asp Asn Tyr Glu Leu Leu Lys His Ser Lys Asn Val 
180 185 190 
Thr Asn Ser Leu Asp Lys Leu Ile Ser Ser Val Ser Ala Phe Thr Ser 
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Ser Asn Asp Ser Arg Asn Val Leu Val Ala Pro Thr Ser Met Arg Ser 
210 215 220 
Thr Pro Asn His Pro Lys Pro Val Leu Val Pro Lys Thr Gln Asn Asn 
225 230 235 240 
Leu Gln Ala Gln Asn Val Pro Gln Ala Gln Asn Ala Ser Gln Ala Gln 
245 250 255 
Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln 
260 265 270 
Val Glu Asn Ala Pro Gln Ala Arg Ser Ser Asp Ser Asn Leu Lys Asp 
275 280 285 
Leu Thr Phe Glu Lys Val Lys His Asn Leu Val Ile Thr Asn Ser Lys 
290 295 300 
Lys Glu Lys Val Thr Ile Gln Asn Trp Phe Arg Glu Ala Asp Phe Ala 
305 310 315 320 
Lys Glu Val Pro Asn Tyr Lys Ala Thr Lys Asp Glu Lys Ile Glu Glu 
325 330 335 
Ile Ile Gly Gln Asn Gly Glu Arg Ile Thr Ser Lys Gln Val Asp Asp 
340 345 350 
Leu Ile Ala Lys Gly Asn Gly Lys Ile Thr Gln Asp Glu Leu Ser Lys 
355 360 365 
Val Val Asp Asn Tyr Glu Leu Leu Lys His Ser Lys Asn Val Thr Asn 
370 375 380 
Ser Leu Asp Lys Leu Ile Ser Ser Val Ser Ala Phe Thr Ser Ser Asn 
385 390 395 400 
Asp Ser Arg Asn Val Leu Val Ala Pro Thr Ser Met Arg Ser Glu Phe 
405 410 415 
Glu Leu Arg Arg Gln Ala Leu Ile Asn 
420 425 
<210> SEQ ID NO 30 
<211> LENGTH, 1278 
<212> TYPE, DNA 
<213> ORGANISM, Mannheimia haemolytica 
<400> SEQUENCE, 30 
atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat 60 
atggctagca tgactggtgg acagcaaatg ggtcgcggat ccacaccgaa tcaccccaaa 120 
ccagtactag taccaaaaac acaaaataat cttcaagcac aaaatgttcc tcaggcacaa 180 
aatgcctctc aggcacaaaa tgcccctcag gcacaaaatg ctcctcaggc acaaaatgct 240 
cctcaggtgg aaaatgctcc tcaggcaaga tcctctgatt cgaacttaaa agatttaaca 300 
tttgaaaaag ttaaacataa tcttgtcatc acgaatagca aaaaagagaa agtgaccatt 360 
caaaactggt tccgagaggc tgattttgct aaagaagtgc ctaattataa agcaactaaa 420 
gatgagaaaa tcgaagaaat catcggtcaa aatggcgagc ggatcacctc aaagcaagtt 480 
gatgatctta tcgcaaaagg taacggcaaa attacccaag atgagctatc aaaagttgtt 540 
gataactatg aattgctcaa acatagcaaa aatgtgacaa acagcttaga taagttaatc 600 
tcatctgtaa gtgcatttac ctcgtctaat gattcgagaa atgtattagt ggctccaact 660 
tcaatgagat ccacaccgaa tcaccccaaa ccagtactag taccaaaaac acaaaataat 720 
cttcaagcac aaaatgttcc tcaggcacaa aatgcctctc aggcacaaaa tgcccctcag 780 
gcacaaaatg ctcctcaggc acaaaatgct cctcaggtgg aaaatgctcc tcaggcaaga 840 
tcctctgatt cgaacttaaa agatttaaca tttgaaaaag ttaaacataa tcttgtcatc 900 










<210> SEQ ID NO 31 
<211> LENGTH, 242 







<213> ORGANISM: Mannheimia haemolytica 







Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 
1 5 10 15 
Arg Gly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg 
20 25 30 
Gly Ser Gly Gly Gly Gly Ser Gln Ala Gln Asn Ala Ser Gln Ala Gln 
35 40 45 
Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln 
50 55 60 
Val Glu Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala 
65 70 75 80 
Pro Gln Gly Gly Gly Gly Ser Phe Arg Glu Ala Glu Phe Ala Lys Thr 
85 90 95 
Ile Gln Asn Tyr Val Ala Thr Arg Asp Asp Lys Ile Glu Glu Ile Ile 
100 105 110 
Gly Gln Asn Gly Glu Arg Ile Gly Gly Gly Gly Ser Arg Ser Gly Gly 
115 120 125 
Gly Gly Ser Gln Ala Gln Asn Ala Ser Gln Ala Gln Asn Ala Pro Gln 
130 135 140 
Ala Gln Asn Ala Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala 
145 150 155 160 
Pro Gln Ala Gln Asn Ala Pro Gln Val Glu Asn Ala Pro Gln Gly Gly 
165 170 175 
Gly Gly Ser Phe Arg Glu Ala Glu Phe Ala Lys Thr Ile Gln Asn Tyr 
180 185 190 
Val Ala Thr Arg Asp Asp Lys Ile Glu Glu Ile Ile Gly Gln Asn Gly 
195 200 205 
Glu Arg Ile Gly Gly Gly Gly Ser Arg Ser Glu Phe Glu Leu Arg Arg 
210 215 220 
Gln Ala Cys Gly Arg Thr Arg Ala Pro Pro Pro Pro Pro Leu Arg Ser 
225 230 235 240 
Gly Cys 
<210> SEQ ID NO 32 
<211> LENGTH, 727 
<212> TYPE, DNA 
<213> ORGANISM: Mannheimia haemolytica 








tgggcagcag ccatcatcat catcatcaca gcagcggcct ggtgccgcgc ggcagccata 60 
54 
US 7,794,734 B2 
55 56 
-continued 
tggctagcat gactggtgga cagcaaatgg gtcgcggatc 
cacaaaatgc ctctcaggca caaaatgccc ctcaggcaca 
atgctcctca ggtggaaaat gctcctcagg cacaaaatgc 
ctcaaggtgg cggtggctcg ttccgtgaag cagagtttgc 
ttgcaacaag agacgataaa attgaagaga ttatcggtca 
gtggtgggtc gagatccggt ggcggcggat ctcaggcaca 
atgcccctca ggcacaaaat gctcctcagg cacaaaatgc 
ctcaggcaca aaatgctcct caggtagaaa atgctcctca 
gtgaagcaga gtttgcaaaa acaattcaaa attatgttgc 
aagagattat cggtcaaaat ggtgaacgga ttggcggtgg 
agctccgtcg acaagcttgc ggccgcactc gagcaccacc 
gctgcta 
<210> SEQ ID NO 33 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Mannheimia haemolytica 
<400> SEQUENCE, 33 
Gln Asn Ala Pro Gln 
1 5 
<210> SEQ ID NO 34 
<211> LENGTH, 4 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 
<400> SEQUENCE, 34 
Gly Gly Gly Ser 
1 
<210> SEQ ID NO 35 
<211> LENGTH, 5 
<212> TYPE, PRT 
spacer 
<213> ORGANISM, Artificial 
<220> FEATURE, 
peptide 
cggtggcggc ggatctcagg 120 
aaatgctcct caggcacaaa 180 
tcctcaggta gaaaatgctc 240 
aaaaacaatt caaaattatg 300 
aaatggtgaa cggattggcg 360 
aaatgcctct caggcacaaa 420 
tcctcaggtg gaaaatgctc 480 
aggtggcggt ggctcgttcc 540 
aacaagagac gataaaattg 600 
tgggtcgaga tccgaattcg 660 
accaccacca ctgagatccg 720 
727 
<223> OTHER INFORMATION, Synthetic linker/spacer sequence 
<400> SEQUENCE, 35 
Gly Gly Gly Gly Ser 
1 5 
We claim: 
1. A purified chimeric protein comprising one or more 
copies of an isolated N-terminal immunodominant epitope of 
recombinant Mannheimia haemolytica Sl outer membrane 
lipoprotein (rPlpE) and one ore more copies of an isolated 
immunodominant epitope of recombinant Mannheimia 
haemolytica leukotoxin (LKT), wherein the immunodomi-
nant epitope of the LKT is mLKT A having the amino acid 
sequence as set forth in SEQ ID No: 21. 
2. The chimeric protein of claim 1, wherein said immun-
odominant epitope of said rPlpE is R2 epitope having the 
amino acid sequence as set forth in SEQ ID No: 19. 
55 3. The chimeric protein of claim 1, wherein said chimeric 
protein further comprises a leader sequence. 
4. The chimeric protein of claim 3, wherein said leader 
sequence is glutathione-S-transferase leader sequence. 
5. The chimeric protein of claim 1, wherein said chimeric 
60 protein further comprises one or more spacer peptides. 
6. The chimeric protein of claim 1, wherein said chimeric 
protein comprises two copies of said rPlpE and two copies of 
saidLKT. 
7. A vaccine preparation comprising at least one purified 
65 chimeric protein comprising one ore more copies of an iso-
lated N-terminal immunodominant epitope of recombinant 
Mannheimia haemolytica Sl outer membrane lipoprotein 
US 7,794,734 B2 
57 
(rPlpE) and one or more copies of an isolated immunodomi-
nant epitope of recombinantMannheimia haemolytica leuko-
toxin (LKT), wherein the immunodominant epitope of the 
LKT is mLKT A having the amino acid sequence as set forth 
in SEQ ID NO: 21, and a physiologically compatible carrier. 5 
8. The vaccine preparation of claim 7, wherein said immu-
nodominant epitope of said rPlpE is R2 epitope having the 
amino acid sequence as set forth in SEQ ID NO: 19. 
9. The vaccine preparation of claim 7, wherein said at least 
one chimeric protein further comprises a leader sequence. 10 
10. The vaccine preparation of claim 9, wherein said leader 
sequence is glutathione-S-transferase leader sequence. 
58 
11. The vaccine preparation of claim 7, wherein said at 
least one chimeric protein further comprises one or more 
spacer peptides. 
12. The vaccine preparation of claim 7, wherein said at 
least one chimeric protein comprises two copies of said rPlpE 
and two copies of said LKT. 
13. The vaccine preparation of claim 7 further comprising 
an adjuvant. 
* * * * * 
